The Physics of Longevity

Age-specific mortality in adult human populations rises roughly exponentially with age, so an intervention can move the hazard's level (delay or prevent a disease; a constant hazard ratio across age strata) or its doubling rate (slow aging), and the two are different quantities. The twelve-hallmark framework (S1) admits a mechanism on three criteria met largely in animal models and does not itself claim a human aging-rate effect; the independent audit of its evidence (S2) finds reliance on lifespan as a proxy, models of unclear relevance and designs without young-treated arms. In the human record this run opened, no perturbation of any hallmark has moved an aging-rate estimand: CANTOS moved a cardiovascular composite in 10,061 post-infarction patients and not all-cause mortality or incident frailty (S9, S10); tafamidis moved all-cause mortality in 441 patients with one protein-misfolding disease (S21); a senolytic pair moved one organ's histology in 31 patients with MASH (S15); CALERIE moved one methylation clock and not two others in 220 randomized adults (S7). Population: human adults in randomized trials and genetic cohorts. Outcome class: all-cause mortality and multi-system function or frailty, against single-disease incidence or a molecular surrogate. Evidence class: INTERVENTION and ARGUMENT. Boundary: this grades identification, not biology; a mechanism can be causal for a disease and still be the right target of a disease trial.

A lever that lowers one cause of death leaves the other causes and the shared repair machinery untouched, so that disease's survival curve shifts (a level change) while the age-dependence of total hazard (the rate) is unchanged. Observed: the endpoints each trial moved and did not move. Inferred: the level-versus-rate decomposition as the estimand that separates them.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 7 cited, 3 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S1 (the three hallmark criteria, framework), S2 (the audit of the hallmark evidence), S7 (CALERIE clocks), S9 and S10 (CANTOS events, all-cause mortality, frailty), S15 (MASH histology), S21 (ATTR-ACT mortality). All four legs traced every hallmark chain to a disease endpoint or surrogate.

• S1Hallmarks of aging: an expanding universe (Cell, 2023)did not openThe twelve hallmarks and the three admission criteria, met largely in animal models; a framework paper, ARGUMENT class.
• S2Targeting the hallmarks of aging to slow aging and treat age-related disease: fact or fiction? (Molecular Psychiatry, 2022)opened, quote confirmedThe hallmark evidence over-relies on lifespan as a proxy, on models of unclear relevance and on designs without young-treated arms, so intervention effects on aging rate are not estimated.
• S7Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial (Nature Aging, 2023)opened, quote confirmedIn 220 randomized adults without obesity, 2 years of caloric restriction slowed DunedinPACE (d about 0.3 at 12 months, 0.2 at 24 months) and did not significantly change PhenoAge or GrimAge; other clocks moved in the opposite direction.
• S9Antiinflammatory therapy with canakinumab for atherosclerotic disease, CANTOS (NEJM, 2017)did not open10,061 post-MI patients with hsCRP >= 2 mg/L, median 3.7 years; 150 mg arm primary composite HR 0.85; hsCRP down 26-41%; all-cause mortality HR 0.94 (0.83-1.06); fatal infection or sepsis 0.31 vs 0.18 per 100 person-years (p=0.02).
• S10Effect of canakinumab on frailty: a post hoc analysis of the CANTOS trial (Aging Cell, 2023)opened, quote confirmedIn 9,942 participants with baseline data, 12.5% of 8,620 non-frail became frail over 5 years on a 34-item cumulative-deficit index (>0.2); canakinumab vs placebo HR 1.03 (0.91-1.17), p=0.63.
• S15Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized controlled trial (Nature Metabolism, 2026; PMID 42823536)did not open31 patients with fibrotic MASH, double-blind, three 7-week cycles: >=1-stage fibrosis improvement without MASH worsening in 47% vs 7% (p=0.02); a one-organ histological endpoint over 21 weeks.
• S21Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, ATTR-ACT (NEJM, 2018)did not open441 patients, 30 months: all-cause mortality 29.5% vs 42.9% (HR 0.70, 0.51-0.96); cardiovascular hospitalization 0.48 vs 0.70 per year (rate ratio 0.68, 0.56-0.81).

Any page sentence that equates a measured hallmark or marker with aging states a disease-risk or surrogate claim; the page may say which instruments track disease risk, never that a marker reports the rate of aging. For the instrument validity and utility vector and the individual experimental inference vector, an aging-rate conclusion is unidentifiable from one body, by construction.

Across the run this is the root law every other vector leans on: no human perturbation of any hallmark has moved an aging-rate quantity, every trial closed at one disease or one surrogate, so the comparator for the page's six ordinary levers and for its instruments is a disease-endpoint comparator, never a rate of aging. The gate holds it at SIGNAL only because twelve of twenty-eight sources would not open and the cross-lab attack came back void, not because any leg or source contradicted it; its content is unanimous across four legs.

In CANTOS (S9), 10,061 patients with a prior myocardial infarction and high-sensitivity CRP of 2 mg/L or more were randomized to canakinumab or placebo and followed a median 3.7 years; the 150 mg arm reduced the primary composite (myocardial infarction, stroke or cardiovascular death) about 15 percent (hazard ratio 0.85), hsCRP fell 26 to 41 percent dose-dependently, fatal infection or sepsis rose to 0.31 from 0.18 per 100 person-years (p=0.02), and all-cause mortality did not differ (hazard ratio 0.94, 95 percent CI 0.83 to 1.06). In the post hoc frailty analysis of 9,942 CANTOS participants with baseline data (S10), 12.5 percent of the 8,620 non-frail at baseline became frail on a 34-item cumulative-deficit index (score above 0.2) over 5 years, and allocation to canakinumab did not change that incidence (hazard ratio 1.03, 95 percent CI 0.91 to 1.17, p=0.63). In 194,418 participants across 47 studies with 46,557 coronary cases (S11), the coronary risk ratio per standard deviation of genetically raised log-CRP was 1.00 (95 percent CI 0.90 to 1.13) against an observational 1.33 (1.23 to 1.43). Population: adults with established atherosclerotic disease and elevated hsCRP; for the genetic result, general adult populations. Outcomes: MACE (major adverse cardiovascular events), all-cause mortality, incident frailty, CHD. Evidence class: INTERVENTION (S9, S10), CORRELATIONAL genetic instrument (S11). Boundary: holds for canakinumab in secondary prevention; it does not grade IL-6 blockade or diet and exercise effects on CRP, which are different exposures.

IL-1β signaling drives plaque inflammation and thrombosis, so neutralizing it lowers atherothrombotic events; the same signaling is load-bearing for host defence, so fatal infections rise and the net death ledger does not move; the cumulative deficits that make up frailty are not downstream of this one cytokine. CRP rises with the pathway but has no causal weight of its own on coronary disease under the genetic instrument. Observed: the hazard ratios, infection rate, frailty incidence and CRP risk ratios. Inferred: that benefit and harm draw on one shared pathway.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 3 cited, 2 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S9 (CANTOS primary: events, hsCRP, infection, all-cause mortality), S10 (CANTOS frailty post hoc), S11 (CRP Mendelian randomisation).

• S9Antiinflammatory therapy with canakinumab for atherosclerotic disease, CANTOS (NEJM, 2017)did not open10,061 post-MI patients with hsCRP >= 2 mg/L, median 3.7 years; 150 mg arm primary composite HR 0.85; hsCRP down 26-41%; all-cause mortality HR 0.94 (0.83-1.06); fatal infection or sepsis 0.31 vs 0.18 per 100 person-years (p=0.02).
• S10Effect of canakinumab on frailty: a post hoc analysis of the CANTOS trial (Aging Cell, 2023)opened, quote confirmedIn 9,942 participants with baseline data, 12.5% of 8,620 non-frail became frail over 5 years on a 34-item cumulative-deficit index (>0.2); canakinumab vs placebo HR 1.03 (0.91-1.17), p=0.63.
• S11Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data (BMJ, 2011)opened, quote confirmed194,418 participants, 47 studies, 46,557 CHD cases: observational RR 1.33 (1.23-1.43) per SD log-CRP against a genetically predicted RR of 1.00 (0.90-1.13); CRP itself is unlikely to be even a modest cause.

A CRP value on a quarterly panel is a disease-risk marker whose own causal weight on coronary disease is about zero; the page may name inflammation as a disease pathway and may not present a falling CRP as slowed aging. For the exercise dose response and comparison vector and the nutrition metabolic health and glucose vector, CRP is an outcome instrument, not a mediator to optimize for its own sake.

Read beside the instrument validity and utility vector's panel axioms, this converts a CRP value on a blood panel from a target into a readout: the pathway is causal for one disease class in one sick population, the measured molecule is not, and the all-cause and frailty ledgers did not move. For the page it means inflammation may be named as a disease pathway and a falling marker may never be read as slowed aging.

Across 35 cancers and 48 non-neoplastic diseases in 420,081 cases and 1,093,105 controls summed across outcomes (S3), genetically longer telomeres raised the odds of 9 of 22 primary cancers and lowered the odds of 6 of 32 primary non-neoplastic diseases (coronary heart disease odds ratio 0.78, 95 percent CI 0.67 to 0.90; abdominal aortic aneurysm 0.63, 0.49 to 0.81; Alzheimer disease 0.84, 0.71 to 0.98; each per standard deviation of genetically predicted telomere length). In 261,837 UK Biobank participants aged 60 and over followed a mean 7.5 years with a 13-variant instrument (S4), each 250 base pairs of genetically longer telomere (about a decade's average attrition) raised cancer odds (odds ratio 1.11, 95 percent CI 1.06 to 1.16), lowered coronary heart disease odds (0.95, 0.92 to 0.98), and showed little association with cognitive function, grip strength, sarcopenia or falls. With 153 variants in about 500,000 UK Biobank participants (S5), genetically longer telomere length was not associated with lifespan in men (0.17 years per standard deviation of log telomere length, 95 percent CI -0.54 to 0.88) or in women (0.04, -0.88 to 0.96). A systematic review of 62 Mendelian randomization studies covering 310 outcomes (S26) reports the same bidirectional pattern. Population: European-ancestry adults in biobanks and case-control consortia. Outcomes: disease odds, lifespan, late-life function. Evidence class: CORRELATIONAL (genetic instruments). Boundary: these are lifelong, small, developmentally compensated shifts in leukocyte telomere length; they do not identify the effect, safety or reversibility of lengthening telomeres in an older adult, and leukocyte length need not be the operative variable in every tissue.

Telomere length sets proliferative reserve in replicating tissues; more reserve preserves vascular and regenerative tissue (fewer degenerative events) and permits more divisions in incipient malignant clones (more cancer), so the effects offset across causes and the net on lifespan is zero within the confidence bounds. Observed: the odds ratios and lifespan estimates. Inferred: antagonistic pleiotropy as the structure behind the sign flip.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 4 cited, 3 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S3 (Haycock 2017, 83 diseases), S4 (Kuo 2019, older adults, function outcomes), S5 (Human Genomics 2025, lifespan), S26 (Deng 2023 systematic review of 62 MR studies).

• S3Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study (JAMA Oncology, 2017)opened, quote confirmedAcross 35 cancers and 48 non-neoplastic diseases (420,081 cases, 1,093,105 controls summed), genetically longer telomeres raised 9 of 22 primary cancers and lowered 6 of 32 non-neoplastic diseases (CHD OR 0.78, AAA 0.63, Alzheimer 0.84 per SD).
• S4Telomere length and aging-related outcomes in humans: a Mendelian randomization study in 261,000 older participants (Aging Cell, 2019)did not openIn 261,837 UK Biobank participants aged 60+, a 13-variant instrument per 250 bp: cancer OR 1.11 (1.06-1.16), CHD OR 0.95 (0.92-0.98), little association with cognitive function, grip strength, sarcopenia or falls.
• S5Biological aging and lifespan in men and women using a Mendelian randomization study (Human Genomics, 2025)opened, quote confirmed153 telomere variants in about 500,000 UK Biobank participants: no lifespan association in men (0.17 years per SD log-TL, 95% CI -0.54 to 0.88) or women (0.04, -0.88 to 0.96); four epigenetic clocks (28 cohorts, n=34,710) null on lifespan in both sexes.
• S26Association between genetically determined telomere length and health-related outcomes: a systematic review and meta-analysis of Mendelian randomization studies (Aging Cell, 2023)opened, quote confirmed62 Mendelian randomization studies covering 310 outcomes show the same bidirectional pattern: longer genetically predicted telomeres raise cancer odds and lower some non-neoplastic disease odds.

A telomere-length test reports a bidirectional disease-risk gradient and no aging rate; the page may not present telomere length as a longevity instrument, and the instrument validity and utility vector grades it as a biomarker with a disease-specific estimand.

A telomere test reports a two-sided disease gradient (cancer up, degenerative disease down) with a net of zero on lifespan under three independent genetic instrument sets; it joins the methylation clock (1.4, 2.4) in the class of biological-age instruments that do not report aging and should not appear on the page's instrument list as if they did.

In CALERIE (S8), 218 adults without obesity were randomized to 25 percent caloric restriction or ad libitum intake for 2 years and the restriction arm achieved 11.7 percent (plus or minus 0.7) restriction of baseline intake; in the methylation analysis of 220 randomized participants (S7), the intervention slowed DunedinPACE (Cohen's d about 0.3 at 12 months and 0.2 at 24 months, p below 0.01, in the 197-participant conference analysis) and did not significantly change PhenoAge or GrimAge, with other clocks moving in the opposite direction. In an epigenome-wide Mendelian randomization of methylation sites against lifespan, healthspan and frailty (S6), neither the existing clocks nor age-related differential methylation were enriched for the putatively causal CpG sites. In 28 cohorts (n=34,710) with genetic instruments for GrimAge, PhenoAge, HannumAge and intrinsic epigenetic age acceleration tested against parental attained age and survival to recruitment (S5), all four clocks showed null associations with lifespan in both sexes. The authors' observational mapping of 3 percent slower DunedinPACE to 15 percent lower mortality in a different cohort is an association, not a trial effect (S25). In 951 Dutch Hunger Winter Families Study participants (S27), in-utero famine exposure associated with faster DunedinPACE six decades later: a clock registers a developmental exposure as a readout. Population: non-obese adults in a trial; biobank adults; a famine birth cohort. Outcomes: clock scores, lifespan. Evidence class: INTERVENTION (S7, S8), CORRELATIONAL genetic (S5, S6), CORRELATIONAL natural experiment (S27), ARGUMENT method (S25). Boundary: the clocks remain valid cohort predictors of mortality, which is their training; this bounds their use as a within-person outcome for an intervention and does not grade the causality-enriched clocks S6 proposes.

Each clock is a regression fit to a different training target (chronological age, a mortality composite, a longitudinal pace), so each weights a different set of CpG sites; a perturbation moves the sites it reaches and leaves the others, and the clocks disagree in direction. A surrogate becomes a mediator only when the intervention's effect on the surrogate carries its effect on the outcome in the same trial (Prentice's criterion), which no clock has met. Observed: the clock effect sizes and signs, the non-enrichment, the null lifespan MR, the famine association. Inferred: that the clocks measure the perturbation rather than the construct.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 6 cited, 4 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S5 (four clocks null on lifespan), S6 (clocks not enriched for causal CpGs), S7 (CALERIE discordance), S8 (CALERIE parent trial, achieved restriction), S25 (surrogate criterion), S27 (famine natural experiment).

• S5Biological aging and lifespan in men and women using a Mendelian randomization study (Human Genomics, 2025)opened, quote confirmed153 telomere variants in about 500,000 UK Biobank participants: no lifespan association in men (0.17 years per SD log-TL, 95% CI -0.54 to 0.88) or women (0.04, -0.88 to 0.96); four epigenetic clocks (28 cohorts, n=34,710) null on lifespan in both sexes.
• S6Causality-enriched epigenetic age uncouples damage and adaptation (Nature Aging, 2024)opened, quote confirmedEpigenome-wide Mendelian randomization found CpG sites causal for lifespan, healthspan and frailty; neither existing epigenetic clocks nor age-related differential methylation are enriched for them.
• S7Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial (Nature Aging, 2023)opened, quote confirmedIn 220 randomized adults without obesity, 2 years of caloric restriction slowed DunedinPACE (d about 0.3 at 12 months, 0.2 at 24 months) and did not significantly change PhenoAge or GrimAge; other clocks moved in the opposite direction.
• S8A 2-year randomized controlled trial of human caloric restriction: feasibility and effects on predictors of health span and longevity (J Gerontol A, 2015)opened, quote confirmed218 adults randomized to 25% caloric restriction or ad libitum for 2 years; the restriction arm achieved 11.7 +/- 0.7 percent; risk factors improved; mortality was not an outcome.
• S25Surrogate endpoints in clinical trials: definition and operational criteria (Statistics in Medicine, 1989)did not openA surrogate is valid only when the treatment effect on the surrogate accounts for the treatment effect on the true outcome; association between the two measures is not enough.
• S27Accelerated biological aging six decades after prenatal famine exposure (PNAS, 2024)did not openIn 951 Dutch Hunger Winter Families Study participants, in-utero famine exposure associated with faster DunedinPACE six decades later: a clock registers a developmental exposure as a readout.

A biological-age test is an instrument whose estimand is its training target; two clocks on one blood draw can disagree in direction after a real intervention, so the page may call a clock a predictor and may not call its change evidence of slowed aging; the instrument validity and utility vector owns the test-retest noise, the individual experimental inference vector the within-person design consequence.

This is the causal half of a law 2.4 states from the measurement side: a methylation clock is a regression fit to a training target, one randomized intervention moves different clocks in different directions, the sites the clocks weight are not enriched for causal methylation, and genetic instruments for four clocks are null on lifespan. The two vectors reached the same bound from different evidence, which is the strongest cross-vector agreement in this run.

In 9 participants with diabetic kidney disease given a 3-day course of the dasatinib-plus-quercetin pair, open-label with no control (S12), adipose p16-positive cells fell 35 percent, p21-positive cells 17 percent and senescence-associated beta-galactosidase activity 62 percent, with circulating IL-1α, IL-6, MMP-9 and MMP-12 lower at 11 days: target engagement in human tissue. In 14 patients with idiopathic pulmonary fibrosis, single-arm and open-label over 3 weeks (S13), 6-minute walk distance rose 21.5 meters and gait speed and chair stands improved, while FEV1, FVC, the frailty index and SASP markers did not change. In 60 postmenopausal women randomized to intermittent treatment or control for 20 weeks (S14), the primary endpoint, percent change in the bone-resorption marker CTx, did not differ (-4.1 percent against -7.7 percent, p=0.611); only the top tertile of baseline T-cell p16 showed exploratory responses. In 31 patients with fibrotic MASH randomized double-blind to intermittent treatment or placebo across three 7-week cycles (S15), 47 percent against 7 percent reached at least one stage of fibrosis improvement without MASH worsening on paired biopsies (p=0.02), a one-organ histological endpoint over 21 weeks. The mouse result that admitted the hallmark (S16): eliminating p16-positive cells from 12 months of age in INK-ATTAC mice raised median lifespan 24 to 27 percent in a mixed background and 24 percent in C57BL/6. Population: patients with one named disease (kidney, lung, bone, liver); mice for the founding result. Outcomes: tissue senescence markers, organ-specific function and histology, a bone-turnover surrogate. Evidence class: INTERVENTION (open-label S12, S13; randomized S14, S15; mouse S16). Boundary: human evidence holds only for disease-defined cohorts with high senescent burden; no trial has a young-treated arm, a multi-system endpoint or an all-cause ledger.

Senescent cells accumulate where injury and replication stress concentrate and secrete a pro-inflammatory, matrix-remodeling program; eliminating them relieves that organ's fibrosis or resorption signal where the burden is high and yields nothing measurable where the burden is ordinary; a multi-kinase inhibitor plus a flavonoid cannot attribute the effect to senescent-cell loss without a rescue arm or a mediator dose-response. Observed: the marker reductions, the null CTx primary, the fibrosis response rates, the mouse lifespan gain. Inferred: the threshold dependence and the attribution problem.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 5 cited, 4 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S12 (engagement pilot, n=9), S13 (IPF pilot, n=14), S14 (bone RCT, n=60, null primary), S15 (MASH RCT, n=31, positive histology), S16 (INK-ATTAC mice).

• S12Senolytics decrease senescent cells in humans: preliminary report from a clinical trial in diabetic kidney disease (EBioMedicine, 2019)opened, quote confirmed9 participants, open-label, no control: adipose p16+ cells down 35%, p21+ down 17%, SA-beta-gal down 62%, circulating IL-1alpha, IL-6, MMP-9 and MMP-12 lower at 11 days.
• S13Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study (EBioMedicine, 2019)opened, quote confirmed14 patients, single arm, 3 weeks: 6-minute walk +21.5 m, gait speed and chair stands improved; FEV1, FVC, frailty index and SASP markers unchanged.
• S14Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (Nature Medicine, 2024)opened, quote confirmed60 women, 20 weeks; primary CTx percent change -4.1% vs -7.7%, p=0.611; exploratory responses only in the top tertile of baseline T-cell p16.
• S15Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized controlled trial (Nature Metabolism, 2026; PMID 42823536)did not open31 patients with fibrotic MASH, double-blind, three 7-week cycles: >=1-stage fibrosis improvement without MASH worsening in 47% vs 7% (p=0.02); a one-organ histological endpoint over 21 weeks.
• S16Naturally occurring p16Ink4a-positive cells shorten healthy lifespan (Nature, 2016)opened, quote confirmedINK-ATTAC mice treated from 12 months: median lifespan up 24-27% (mixed background) and 24% (C57BL/6), with multi-organ healthspan gains; the founding mouse result for the senescence hallmark.

The page may not treat senescence as a lever in a healthy adult; the hormones supplements and drugs as evidence vector should grade senolytics as organ-specific disease candidates with one positive randomized histological result and a null primary elsewhere.

Senolytics are the exotic lever mouse biology most favors, and in humans they have one positive organ-specific randomized histology result in thirty-one patients, a null prespecified primary in bone, and engagement pilots with no control. This sizes the exotic side of the page's not-exotic comparison, which the exercise dose response and comparison vector adjudicated without an exotic comparator of its own because the hormones supplements and drugs as evidence vector never ran.

In 218 older adults randomized to low-dose everolimus or placebo (S18), the influenza vaccine response rose about 20 percent and the share of PD-1-positive CD4 and CD8 T cells fell: an immune surrogate moved. In the phase 3 trial of the mTOR inhibitor RTB101 in 1,024 older adults over a 16-week winter season (S19), clinically symptomatic respiratory illness occurred in 26 percent on drug against 25 percent on placebo (p=0.65) despite upregulated interferon-induced antiviral genes, after a phase 2b of 652 had shown 19 percent against 28 percent laboratory-confirmed infections (p=0.02). In PEARL (S20), 114 completers aged 50 to 85 randomized to weekly compounded rapamycin at two doses or placebo for 48 weeks showed no change in the primary endpoint, visceral adiposity by DXA (partial eta squared 0.001, p=0.942); lean mass and self-reported pain improved only among women on the higher dose, a subgroup of 8 on secondary endpoints. In the Ecuadorian growth-hormone-receptor-deficiency cohort (S17), 99 individuals with lifelong IGF-1 deficiency against 1,606 unaffected relatives had one cancer death against cancer as 20 percent of relatives' deaths, and 0 percent diabetes (95 percent CI 0 to 4) against about 5 to 6 percent; serum from affected individuals lowered oxidant-induced DNA damage in cultured cells, an effect fully reversed by adding 200 ng/mL IGF-1 back, a human ex vivo add-back that identifies the mediator. No lifespan extension was demonstrated in that cohort and childhood mortality was elevated. Population: healthy older adults in trials; a lifelong loss-of-function kindred. Outcomes: vaccine titers, respiratory infection incidence, visceral fat, cancer and diabetes incidence, lifespan. Evidence class: INTERVENTION (S18, S19, S20), CORRELATIONAL natural cohort with an ex vivo INTERVENTION (S17). Boundary: trial results hold for the doses, durations and populations named; compounded rapamycin in PEARL had about one third the bioavailability of the commercial form, so a null there is a null for that exposure; the add-back identifies IGF-1 as the mediator of the cell phenotype, not of lifespan.

Growth-hormone, IGF-1 and mTOR signaling scale anabolism and proliferation; damping them lowers the diseases of proliferation and glucose load (cancer, diabetes) and partially restores an exhausted immune repertoire, while the same signaling supports growth, glucose handling and repair, so a complete lifelong knockdown takes away two causes of death without extending life and a pharmacological knockdown moves a surrogate without moving a clinical primary. Observed: the titers, infection rates, the null primary, the cancer and diabetes counts, the reversal by IGF-1. Inferred: that disease causation here does not entail aging-rate causation.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 4 cited, 2 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S17 (GHR-deficiency cohort and IGF-1 add-back), S18 (everolimus and vaccine response), S19 (RTB101 phase 2b and phase 3), S20 (PEARL).

• S17Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer and diabetes in humans (Science Translational Medicine, 2011)opened, quote confirmed99 GHR-deficient individuals vs 1,606 relatives: one cancer death vs cancer as 20% of relatives' deaths; diabetes 0% (95% CI 0-4) vs about 5-6%; serum lowered oxidant DNA damage in cells, fully reversed by adding 200 ng/mL IGF-1; no lifespan extension shown.
• S18mTOR inhibition improves immune function in the elderly (Science Translational Medicine, 2014)did not openIn 218 older adults randomized to low-dose everolimus or placebo, influenza vaccine response rose about 20% and PD-1-positive CD4 and CD8 T cells fell.
• S19Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials (Lancet Healthy Longevity, 2021; PMID 33977284)did not openPhase 2b (652): laboratory-confirmed infections 19% vs 28% (p=0.02); phase 3 (1,024): clinically symptomatic respiratory illness 26% vs 25% (p=0.65) despite upregulated antiviral genes.
• S20Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results (Aging, 2025)opened, quote confirmed114 completers aged 50-85, 48 weeks, weekly compounded rapamycin at two doses vs placebo: visceral adiposity unchanged (partial eta squared 0.001, p=0.942); lean mass and pain improved only in women on the higher dose (n=8), secondary endpoints.

the hormones supplements and drugs as evidence vector sizes rapamycin as a drug with a human immune surrogate and no clinical primary met in a healthy or normative-aging cohort; the exotic lever mouse biology most favors has not produced a human clinical primary, which is evidence for the exercise dose response and comparison vector's comparator on the not-exotic claim.

mTOR inhibition moved an immune surrogate and no clinical primary in healthy older adults, and a lifelong human knockdown of growth-hormone signaling removed two diseases without extending life; with 1.5 it supplies the only exotic-lever evidence this run holds, and it says the exotic side has not produced a human clinical primary in a normative-aging cohort.

Mendelian randomization identifies an exposure's effect only when the variants predict the exposure (relevance), are unrelated to confounders (independence) and reach the outcome only through the exposure (exclusion); what it identifies is a lifelong small shift set at conception and buffered by development, so it licenses the sign of an effect and whether a target is futile, never the effect of a late-life, large, uncompensated change. The telomere record shows the dependence on instrument quality: a 13-variant instrument in 261,837 older adults (S4), a multi-trait set across 420,081 cases (S3) and a 153-variant set in about 500,000 participants (S5) agree, while the anthropic leg records a 7-variant score that once gave the opposite cardiovascular sign. The CRP result (S11) shows exclusion doing its work: the observational risk ratio 1.33 fell to 1.00 under the instrument. Somatic natural experiments reverse the trade: in four case-control cohorts (4,726 coronary cases, 3,529 controls) plus prospective cohorts (S22), carriers of clonal hematopoiesis had about 1.9-fold coronary heart disease risk (95 percent CI 1.4 to 2.7) and 4.0-fold early-onset myocardial infarction (2.4 to 6.7), with coronary calcification rising with the mutations and Tet2-deficient marrow enlarging aortic lesions in mice; in 97,691 whole genomes (S23) an inherited IL6R loss-of-function variant attenuated the cardiovascular risk associated with CHIP, a natural rescue arm for the proposed mediator. A somatic clone grows in the right tissue at the right age without developmental buffering, but clone size is endogenous to the inflammatory and proliferative stresses that also cause the outcome. Population: European-ancestry biobank adults; coronary case-control cohorts. Outcomes: disease odds, lifespan, coronary events. Evidence class: CORRELATIONAL (genetic and somatic instruments; S22 adds a mouse INTERVENTION). Boundary: neither design identifies a treatment effect; a drug's dose, duration and age window need a randomized trial; the IL6R attenuation estimate is not carried because only the paper's identity was confirmed.

Randomization at conception removes confounding but fixes the exposure's size and timing to a lifelong, buffered shift; a somatic clone supplies the right dose, tissue and age window but is itself a product of the exposure field, so the two designs carry non-overlapping biases and their agreement, not either alone, is the evidence. Observed: the instrument-set estimates, the CRP contrast, the CHIP risk ratios and the IL6R attenuation. Inferred: the orthogonal-bias reading of germline against somatic designs.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed PROBABLE) · Refuted by the adversary on a claim no opened source could verify · Sources: 6 cited, 3 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed PROBABLE -> granted SIGNAL (gate lowers, never raises)

S3, S4, S5 (three telomere instrument sets), S11 (CRP exclusion at work), S22 (CHIP risk and dose response), S23 (IL6R natural rescue arm).

• S3Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study (JAMA Oncology, 2017)opened, quote confirmedAcross 35 cancers and 48 non-neoplastic diseases (420,081 cases, 1,093,105 controls summed), genetically longer telomeres raised 9 of 22 primary cancers and lowered 6 of 32 non-neoplastic diseases (CHD OR 0.78, AAA 0.63, Alzheimer 0.84 per SD).
• S4Telomere length and aging-related outcomes in humans: a Mendelian randomization study in 261,000 older participants (Aging Cell, 2019)did not openIn 261,837 UK Biobank participants aged 60+, a 13-variant instrument per 250 bp: cancer OR 1.11 (1.06-1.16), CHD OR 0.95 (0.92-0.98), little association with cognitive function, grip strength, sarcopenia or falls.
• S5Biological aging and lifespan in men and women using a Mendelian randomization study (Human Genomics, 2025)opened, quote confirmed153 telomere variants in about 500,000 UK Biobank participants: no lifespan association in men (0.17 years per SD log-TL, 95% CI -0.54 to 0.88) or women (0.04, -0.88 to 0.96); four epigenetic clocks (28 cohorts, n=34,710) null on lifespan in both sexes.
• S11Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data (BMJ, 2011)opened, quote confirmed194,418 participants, 47 studies, 46,557 CHD cases: observational RR 1.33 (1.23-1.43) per SD log-CRP against a genetically predicted RR of 1.00 (0.90-1.13); CRP itself is unlikely to be even a modest cause.
• S22Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease (NEJM, 2017)did not openFour case-control cohorts (4,726 CHD cases, 3,529 controls) and prospective cohorts: CHIP carriers had CHD HR about 1.9 (1.4-2.7) and early-onset MI OR 4.0 (2.4-6.7); coronary calcification rose with the mutations; Tet2-deficient marrow enlarged aortic lesions in mice.
• S23Inherited causes of clonal haematopoiesis in 97,691 whole genomes (Nature, 2020)did not open97,691 whole genomes, 4,229 with CHIP; an inherited IL6R loss-of-function variant attenuated the cardiovascular risk associated with CHIP, a natural rescue arm for the IL-6 mediator (identity confirmed; the estimate is not carried).

When a page or vendor cites a marker as genetically proven, the proof is a sign and a non-futility, not a dose; the instrument validity and utility vector and the hormones supplements and drugs as evidence vector should not convert a genetic effect per standard deviation into a treatment target.

The rule for reading every genetic result cited elsewhere in the run: 3.1's fitness null, 4.5's alcohol instrument and 4.6's apoB instrument each identify a sign and a target's non-futility for a lifelong small shift, never a dose, a duration or an age window for a late-life change. A page or vendor sentence that says genetically proven is making a sign claim.

In ATTR-ACT (S21), 441 patients with transthyretin amyloid cardiomyopathy randomized to tafamidis or placebo for 30 months had all-cause mortality of 29.5 percent against 42.9 percent (hazard ratio 0.70, 95 percent CI 0.51 to 0.96) and cardiovascular hospitalization 0.48 against 0.70 per year (rate ratio 0.68, 0.56 to 0.81): a proteostasis mechanism closes to survival in one disease, which is a disease result and not a slowing of aging. In MMPOWER-3 (S24), 218 people with genetically confirmed primary mitochondrial myopathy randomized to elamipretide or placebo for 24 weeks did not meet the primary walking and fatigue endpoints: a null for that peptide at that dose in that population, not evidence that mitochondrial defects are non-causal, because a trial can fail at the target, the tissue, the downstream function, the timing relative to irreversible damage, the balance of harms or the endpoint. Randomizing a treatment does not randomize the mediator; a post-treatment marker adjusted into an outcome regression does not identify mediation without further assumptions (S28), and a surrogate carries a treatment effect only when the treatment's effect on the surrogate accounts for its effect on the outcome in the same trial (S25). Population: patients with one named disease. Outcomes: all-cause mortality and hospitalization; functional endpoints. Evidence class: INTERVENTION (S21, S24), ARGUMENT method (S25, S28). Boundary: grades the logic of transfer; it does not grade tafamidis or elamipretide as treatments.

A hallmark label names a family of variables and of possible interventions; each trial tests one member at one dose in one population against one endpoint, so its result transfers only along the dimensions it held fixed, and a positive or null reading of the label as a whole is a category error. Observed: the ATTR-ACT and MMPOWER-3 endpoints. Inferred: the failure-mode list for a null and the tuple rule, from the method sources.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed PROBABLE) · Refuted by the adversary on a claim no opened source could verify · Sources: 4 cited, 1 opened and confirmed

• ATTACK VOID: the refutation rests on a source that would not open (reason_class unverifiable), a miss, never a refutation; neither a kill nor a pass, the grade follows the sources test alone
• citations: refetched 57% (>=90%), resolved 100% (>=80%) -> BELOW FLOOR
• dead links: 12 of 28 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED SIGNAL: neither a grounded cross-lab adversary survived nor sources confirmed
• CLAMPED: claimed PROBABLE -> granted SIGNAL (gate lowers, never raises)

S21 (ATTR-ACT: positive mortality result in one disease), S24 (MMPOWER-3: null primaries), S25 (surrogate criterion), S28 (mediation is not randomized by randomizing treatment).

• S21Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, ATTR-ACT (NEJM, 2018)did not open441 patients, 30 months: all-cause mortality 29.5% vs 42.9% (HR 0.70, 0.51-0.96); cardiovascular hospitalization 0.48 vs 0.70 per year (rate ratio 0.68, 0.56-0.81).
• S24Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial (Neurology, 2023)did not open218 people with genetically confirmed primary mitochondrial myopathy, 24 weeks: the primary walking and fatigue endpoints were not met; a null for that exposure in that population, not a null mechanism.
• S25Surrogate endpoints in clinical trials: definition and operational criteria (Statistics in Medicine, 1989)did not openA surrogate is valid only when the treatment effect on the surrogate accounts for the treatment effect on the true outcome; association between the two measures is not enough.
• S28Imai, Keele and Tingley on causal mediation and the limits of the Baron-Kenny procedureopened, quote confirmedRandomizing a treatment does not randomize the mediator; adjusting an outcome regression for a post-treatment marker does not identify mediation without further assumptions.

When the page or a vendor says a mechanism works or failed, the question is which tuple was tested; the individual experimental inference vector's self-experiment inherits the same rule, a within-person null is a null for that exposure and window only.

The transfer rule the self-experiment inherits even though the individual experimental inference vector never ran: a result attaches to the tuple of perturbation, dose, window, population and endpoint, so a within-person null is a null for that exposure and window only, and a positive disease trial is not an aging result. 3.7 states the same discipline for ranking levers across studies.

For one person, two laboratory results differ by biological and analytical noise before any real change enters; the smallest difference distinguishable from no change at a 95 percent criterion is RCV = 1.96 x sqrt(2) x sqrt(CV_A^2 + CV_I^2), about 2.8 combined single-result CVs. Population: healthy adults sampled under protocol; outcome: a biomarker's change against its test-retest noise; design: within-person biological-variation studies (CORRELATIONAL). Measured components: creatinine within-subject CV 5.2 percent (95 percent CI 4.6 to 5.8) pooled from 37 studies and 2,770 participants, giving an eGFR RCV of plus or minus 12.5 to 16.5 percent (S3, 2022); LDL cholesterol within-subject CV 8.7 percent by direct assay, 9.3 by Friedewald, 9.0 by Martin-Hopkins in healthy adults, which with an analytical CV near 2.5 percent gives a two-result RCV near 26 percent of the value (S5, 2026; the 26 percent is arithmetic from the published components); HbA1c within-individual total variation 0.091 in non-diabetic primary-care patients among 587,023 patients, over five times the EFLM database biological-variation figure of 0.016, because routine collection adds pre-analytical variation that controlled studies exclude (S6, 2025); indirect RCVs from routine laboratory data are similar to but wider than formula RCVs, creatinine minus 16 to plus 14 percent (S8, 2024). Of 61 biological-variation papers appraised for kidney markers, 3 earned grade A, 4 B and 48 C (S4), so database inputs carry their own uncertainty. Boundary: the protocol CV_I is a lower bound on the variation a person meets in routine collection; a population reference interval (CV_G) is not an individual's change threshold.

The variance of a difference between two independent draws is the sum of the two variances (the sqrt 2); each draw's variance is the sum of independent biological and analytical components (the root-sum-square); a reference interval describes between-person spread, not one person's set point. Observation: the CV components and the real-world HbA1c figure. Inference: the RCV arithmetic and the lower-bound claim.

Granted tier: PROBABLE, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 6 cited, 4 opened and confirmed

• PROBATION: 1 misquote flag elsewhere in this vector (below the kill line of 2); this axiom's own sources were clean -> capped at PROBABLE
• survived a grounded cross-lab adversary (google vs authors ["anthropic"])
• citations: refetched 89% (>=90%), resolved 97% (>=80%) -> BELOW FLOOR
• dead links: 4 of 35 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED PROBABLE: one of {grounded cross-lab adversary, verified sources} but not both
• CLAMPED: claimed FORGED -> granted PROBABLE (gate lowers, never raises)

S1 (measurement model, ARGUMENT standard) and S3, S4, S5, S6, S8 (biological-variation measurements and routine-data RCVs).

• S1JCGM 100:2008 Guide to the expression of uncertainty in measurement (BIPM)opened, quote confirmedThe measurement model: an instrument estimates a defined quantity with bias and random error; the estimand precedes precision (ARGUMENT, metrology standard, 2008).
• S3Thoni et al. 2022, Frontiers in Medicine: biological variation and RCV of eGFR, meta-analysisopened, quote confirmedCreatinine within-subject CV 5.2 percent (95 percent CI 4.6 to 5.8) pooled from 37 studies and 2,770 participants; eGFR RCV plus or minus 12.5 to 16.5 percent (CORRELATIONAL, 2022).
• S4Jonker et al. 2022, CCLM: critical appraisal and meta-analysis of biological variation for kidney analytesdid not openOf 61 biological-variation papers appraised, 3 graded A, 4 B, 48 C, 5 D; database inputs carry their own uncertainty (CORRELATIONAL meta-appraisal, 2020/2022).
• S5Scand J Clin Lab Invest 2026: biological variation of direct and indirect LDL cholesterol in healthy individualsdid not openLDL-C within-subject CV 8.7 (direct), 9.3 (Friedewald), 9.0 (Martin-Hopkins) percent; between-subject CV 14.7, 18.5, 18.6 percent in healthy adults (CORRELATIONAL, 2026).
• S6PLOS ONE 2025: within-individual variation of HbA1c measurements in primary care, 587,023 patientsopened, quote confirmedReal-world within-individual HbA1c CV 0.200 overall and 0.091 in non-diabetic patients, over five times the EFLM database figure of 0.016 (CORRELATIONAL, routine data, 2025).
• S8Clinical Chemistry 2024/2025: estimating reference change values using routine patient dataopened, quote confirmedIndirect RCVs from routine laboratory data (2015 to 2023, 10 analytes) are similar to but wider than formula RCVs; creatinine minus 16 to plus 14 percent (CORRELATIONAL, routine data).

A panel result moves a decision only when the change clears the analyte's RCV computed from the collection process actually used: roughly a quarter of the LDL value on one pair of draws, and for HbA1c under routine collection no move under about a full percentage point is readable in a non-diabetic adult. The page may call panels instruments; it may not imply that a quarterly delta below these floors is information.

The floor under the page's quarterly panels: two draws from one person differ by biological plus analytical noise before anything changes, about 2.8 combined coefficients of variation, and routine collection widens the floor past the database value (five times for HbA1c in a 587,023-patient primary-care record). This is one of six axioms the gate granted PROBABLE in the run, and it is the one that most directly rewrites a page sentence.

In healthy adults, each analyte judged against a 95 percent reference interval flags about 5 percent of the time with no disease present, so k analytes read t times a year flag at least once with probability 1 minus 0.95^(kt) under independence: 20 analytes once, 64 percent; 20 analytes quarterly, 98 percent and four expected flags a year (MODEL arithmetic; correlation among analytes lowers the real figure but not to a small one). The measured analogue in repeated screening is the PLCO trial: among 68,436 adults aged 55 to 74, the cumulative risk of at least one false-positive result after 14 screening tests was 60.4 percent in men and 48.8 percent in women, and 28.5 percent of men and 22.1 percent of women underwent an invasive procedure prompted by a false positive (S9, 2009; CORRELATIONAL within a randomized trial; outcome: false-positive and procedure incidence). The second engine is regression to the mean: with between-person reliability rho = CV_G^2 / (CV_G^2 + CV_I^2 + CV_A^2), a value one SD above the mean reverts a fraction 1 minus rho on retest with no intervention; from LDL CV_G 18.6 and CV_I 9.0 percent rho is about 0.80 (S5), and from HbA1c CV_G 7.9 percent (S35) against the real-world non-diabetic within-person 9.1 percent (S6) rho is about 0.43, so more than half of an apparent HbA1c elevation disappears on retest by arithmetic (the rho values are this writer's computation from published components). The only quarterly rationale in an opened guideline is disease management: HbA1c at least quarterly when therapy changes or goals are unmet, twice yearly when stable (S34, 2023).

Independent tests compound their false-flag probabilities multiplicatively, and a selected extreme value carries a noise component that is not expected to repeat. Observation: the PLCO counts and the CV components. Inference: the binomial and rho arithmetic, and the reading of the guideline cadence as disease management rather than surveillance.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a source said less than the claim · Sources: 5 cited, 2 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S34 (number_not_on_page) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S9 (PLCO false-positive incidence), S5 and S35 and S6 (CV components for the reversion fractions), S34 (the guideline cadence).

• S5Scand J Clin Lab Invest 2026: biological variation of direct and indirect LDL cholesterol in healthy individualsdid not openLDL-C within-subject CV 8.7 (direct), 9.3 (Friedewald), 9.0 (Martin-Hopkins) percent; between-subject CV 14.7, 18.5, 18.6 percent in healthy adults (CORRELATIONAL, 2026).
• S6PLOS ONE 2025: within-individual variation of HbA1c measurements in primary care, 587,023 patientsopened, quote confirmedReal-world within-individual HbA1c CV 0.200 overall and 0.091 in non-diabetic patients, over five times the EFLM database figure of 0.016 (CORRELATIONAL, routine data, 2025).
• S9Croswell et al. 2009, Annals of Family Medicine: cumulative incidence of false-positive results in repeated multimodal cancer screening (PLCO)opened, quote confirmedAmong 68,436 adults aged 55 to 74, cumulative risk of at least one false positive after 14 tests 60.4 percent in men and 48.8 percent in women; invasive procedure from a false positive 28.5 and 22.1 percent (CORRELATIONAL within an RCT, 2009).
• S34Clinical Chemistry 2023: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetesopened, the number was not on the pageHbA1c testing at least quarterly when therapy changes or glycemic goals are unmet, at least twice yearly when stable; a disease-management cadence tied to erythrocyte integration, not healthy-adult surveillance (ARGUMENT, guideline, 2023).
• S35Scand J Clin Lab Invest 2024: within- and between-subject biological variation of whole blood HbA1c in 38 apparently healthy adultsdid not openHbA1c within-subject CV 2.9 percent, between-subject 7.9 percent, index of individuality 0.37, so the population interval is a weak detector of one person's change (CORRELATIONAL, healthy adults, 2024).

The analytes to be acted on, their thresholds and the action are written down before the draw; analytes outside that list are not evidence. A flag is confirmed by a replicate, never escalated from one result. 'Quarterly' is a calendar word, not a sampling law; the page's quarterly cadence is bounded to this discipline.

Many analytes at a fixed cadence compound their five-percent false flags and a flagged extreme reverts toward the mean on retest; the measured analogue is the PLCO screening count. The gate clamped it to SIGNAL on a tripwire (a number cited to a guideline that was not on that page), so the quarterly-cadence refutation rests on this and 2.3 at SIGNAL while the RCV floor beneath it (2.1) stands at PROBABLE.

In healthy adults, the within-person CV of a drifting analyte measured monthly exceeds its CV measured daily: for small dense LDL cholesterol the within-subject CV was 9.4 percent on daily fasting draws and 17.1 percent on monthly draws, with monthly within-subject CVs of 17.1 percent (sdLDL-C), 7.4 (HDL3-C) and 25.7 (TRL-C) and a monthly RCV of 18.1 mg/dL against a mean near 28 mg/dL (S7, 2022; CORRELATIONAL within-person; outcome: biomarker change against its noise at two intervals). Because the RCV of a mean of n replicates falls as 1 over sqrt n while CV_I rises with the interval, two draws a week apart averaged cut LDL's single-pair RCV from about 26 to about 18 percent and three to about 15 percent (arithmetic from the S5 components), whereas four quarterly singletons each carry the full interval-inflated CV_I. The analyte's integration time sets the shortest useful interval: HbA1c integrates glycation over erythrocyte survival, which is why the opened guideline's shortest cadence is about three months (S34). Boundary: shown directly for lipid subfractions in healthy adults; the generalization to other drifting analytes is inference from the variance model.

Slow drift and seasonal components enter the within-person variance only when the interval is long enough for them to act; averaging independent replicates shrinks random error but not drift. Observation: the daily-versus-monthly CVs. Inference: the clustered-replicate design rule.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed PROBABLE) · Refuted by the adversary on single source · Sources: 3 cited, 1 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S34 (number_not_on_page) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed PROBABLE -> granted SIGNAL (gate lowers, never raises)

S7 (daily versus monthly within-person CV), S5 (LDL components for the replicate arithmetic), S34 (HbA1c integration cadence).

• S5Scand J Clin Lab Invest 2026: biological variation of direct and indirect LDL cholesterol in healthy individualsdid not openLDL-C within-subject CV 8.7 (direct), 9.3 (Friedewald), 9.0 (Martin-Hopkins) percent; between-subject CV 14.7, 18.5, 18.6 percent in healthy adults (CORRELATIONAL, 2026).
• S7J Appl Lab Med 2022: short- and long-term biological variability of sdLDL-C, HDL3-C and TRL-Copened, quote confirmedMonthly within-subject CV 17.1 percent sdLDL-C, 7.4 HDL3-C, 25.7 TRL-C; daily-fasting sdLDL-C CV 9.4 percent doubling to 17.1 monthly; monthly RCV 18.1 mg/dL on a mean near 28 (CORRELATIONAL within-person, 2022).
• S34Clinical Chemistry 2023: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetesopened, the number was not on the pageHbA1c testing at least quarterly when therapy changes or glycemic goals are unmet, at least twice yearly when stable; a disease-management cadence tied to erythrocyte integration, not healthy-adult surveillance (ARGUMENT, guideline, 2023).

A change is tested with a replicate pair before and after the intervention, spaced by the analyte's response time (weeks for lipids, about three months for HbA1c), not by the quarter; the next legitimate draw is at the next decision. Advanced lipid subfractions are refuted for serial personal monitoring at any cadence because their RCV is near two thirds of the mean.

Within-person variation grows with the sampling interval for drifting analytes, so replicates clustered before and after a decision beat singletons spread across the calendar; one opened within-person study carries the interval mechanism and the gate's tripwire on a shared source holds it at SIGNAL. It is the design rule a self-experiment on blood markers would use, which is why the individual experimental inference vector's absence is felt here.

Technical noise causes six major clocks to deviate 3 to 9 years between replicate assays of one sample, and principal-component versions bring most replicates within 1 year (S10, 2021; S11, 2022; MODEL on technical replicates); DunedinPACE test-retest ICC is 0.96 (95 percent CI 0.93 to 0.98) in 36 replicates and 0.87 in 350 (S13, 2022). Across 18 methylation clocks in four datasets (technical replicates in 196 and 128 individuals; biological replicates under meals, stress, altitude and pollution in 21 to 34 per condition), most clocks had technical ICC above 0.90 but biological short-interval ICC of about 0.4 to 0.7 with none excellent, and the two reliabilities were independent (r 0.0168) (S12, Aging Cell, July 2026; CORRELATIONAL). Prognosis: among 2,105 NHANES adults aged 50 and over followed a median 17.5 years with 998 deaths, GrimAge acceleration carried a mortality hazard ratio of 1.50 (1.32 to 1.71) per 5 years and Hannum, PhenoAge and Horvath 1.13 to 1.16 (S15, 2024 preprint; outcome: all-cause mortality). Surrogacy: in CALERIE, 220 adults without obesity randomized to 25 percent calorie restriction or ad libitum for two years, DunedinPACE slowed while PhenoAge and GrimAge did not change significantly, with small effects (S14, 2023; INTERVENTION); no biomarker of aging is a validated surrogate endpoint (S16, 2024; S2). Smallest real change in one person (MODEL arithmetic): MDC95 = 2.77 x SD x sqrt(1 minus ICC); with a DunedinPACE SD of 0.15 pace-units and a biological ICC of 0.70, MDC95 is about 0.23 pace-units, two to three times the 10 percent unit in which its mortality association is expressed. Boundary: cohort prognosis holds for middle-aged and older adults; the individual refutation holds for repeat tests over months to a year in any adult.

A clock is a regression over methylation at selected CpG sites in a leukocyte mixture; averaging across principal components removes array noise but not the day-to-day biology (cell composition, meals, stress) that moves its inputs; the attenuation theorem caps a measure's correlation with any truth at the square root of its ICC. Observation: the ICCs, hazard ratios and CALERIE effects. Inference: the MDC arithmetic and the refutation of the individual-feedback use.

Granted tier: PROBABLE, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 8 cited, 8 opened and confirmed

• PROBATION: 1 misquote flag elsewhere in this vector (below the kill line of 2); this axiom's own sources were clean -> capped at PROBABLE
• survived a grounded cross-lab adversary (google vs authors ["anthropic"])
• citations: refetched 89% (>=90%), resolved 97% (>=80%) -> BELOW FLOOR
• dead links: 4 of 35 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED PROBABLE: one of {grounded cross-lab adversary, verified sources} but not both
• CLAMPED: claimed FORGED -> granted PROBABLE (gate lowers, never raises)

S10, S11, S13 (technical reliability), S12 (biological reliability), S15 (cohort prognosis), S14 (randomized intervention response), S16 and S2 (surrogate status).

• S2FDA surrogate endpoint resourcesopened, quote confirmedSurrogate validity requires that an intervention-induced change in the marker predict a specified clinical benefit; prediction alone is not surrogacy (ARGUMENT, regulatory definition).
• S10Higgins-Chen et al. 2021, Innovation in Aging: a computational solution to bolster epigenetic clock reliabilityopened, quote confirmedTechnical noise causes six major clocks to deviate 3 to 9 years between replicates; principal-component clocks agree within 1 year (MODEL on technical replicates, 2021).
• S11Higgins-Chen et al. 2022, Nature Aging: principal-component epigenetic clocksopened, quote confirmedOver 90 percent of technical replicates agree within about 1 to 1.5 years for PC clocks; age-acceleration reliability is lower than age reliability (MODEL on replicates, 2022).
• S12Aging Cell, July 2026: biological versus technical reliability of epigenetic clocksopened, quote confirmedAcross 18 methylation clocks, technical ICC above 0.90 for most but biological short-interval ICC about 0.4 to 0.7, none excellent; technical and biological reliability independent (r 0.0168); replicates in 196 and 128 individuals, 21 to 34 per perturbation (CORRELATIONAL, 2026).
• S13Belsky et al. 2022, eLife: DunedinPACE, a DNA methylation biomarker of the pace of agingopened, quote confirmedDunedinPACE test-retest ICC 0.96 (0.93 to 0.98) in 36 replicates, 0.97 in 28, 0.87 in 350 (MODEL on replicates, 2022).
• S14Waziry et al. 2023, Nature Aging: long-term caloric restriction and DNA methylation measures of aging in CALERIEopened, quote confirmed220 adults without obesity randomized to 25 percent calorie restriction or ad libitum for two years: DunedinPACE slowed; PhenoAge and GrimAge did not change significantly; small effects (INTERVENTION, 2023).
• S15Epigenetic age acceleration and mortality risk prediction in U.S. adults (NHANES), 2024 preprintopened, quote confirmed2,105 adults aged 50 and over, median 17.5 years, 998 deaths: GrimAge acceleration HR 1.50 (1.32 to 1.71) per 5 years; Hannum 1.16, PhenoAge 1.13, Horvath 1.13 (CORRELATIONAL, 2024).
• S16Moqri et al. 2024, Nature Medicine: validation of biomarkers of agingopened, quote confirmedNo consensus validation framework exists and no biomarker of aging is validated as a surrogate endpoint (ARGUMENT, consensus review, 2024).

A clock is a cohort-science and trial-response marker; one person's repeat test a year apart measures the assay, the leukocyte differential and the week more than their aging, so a clock does not enter the page's instrument list as a feedback instrument. If used at all: the same tissue, platform, pipeline and clock version, technical replicates, and the result read against a prespecified MDC.

The measurement half of the clock law 1.4 states causally: technical reliability after principal-component reconstruction is high, biological reliability over days is fair to moderate and independent of it, cohort prognosis is real, surrogacy is unproven, and the smallest readable within-person change exceeds the unit in which the mortality association is expressed. Granted PROBABLE, it is the strongest refutation in the run of a biological-age test as a personal feedback instrument.

The physiological delay of glucose from blood to interstitial fluid in overnight-fasted adults is about 5 to 6 minutes by tracer (S17, 2013; INTERVENTION in humans), but in vivo sensors reach maximum current 24 plus or minus 7 minutes after a glucose rise against 2 plus or minus 1 minutes for blood and 35 plus or minus 2 seconds in vitro, and the delay correlates with collagen deposited around the filament (R 0.96), so encapsulation, which grows over the wear period, is the dominant lag (S18, 2019; INTERVENTION in mice; transfer to humans is inference). MARD is a mean absolute relative difference, not an error bound; the error bound is the agreement rate. In the pivotal study of 316 adults with diabetes, MARD was 8.2 percent (arm) and 9.1 percent (abdomen), with 89.6 and 85.5 percent of readings within 15 mg/dL or 15 percent of reference and 95.3 and 93.2 percent within 20/20 (S19, 2022; controlled clinic comparison), so about one reading in ten misses by more than 15. In 39 young adults without diabetes wearing over-the-counter sensors against a capillary meter, MARD was 12.9 percent, bias minus 4.8 mg/dL, 66.5 percent of readings within 15/15, population lag 6.2 minutes, and MARD rose from 10.6 to 15.3 percent after sugar versus placebo (S20, September 2026; the reference was a meter, not laboratory plasma). Boundary: the pivotal figures describe adults with diabetes in clinic; the 39-person figures describe young non-diabetic adults against a meter.

The sensor reads current at an electrode inside a fibrous capsule in subcutis, three substitutions from plasma glucose (compartment, filter, encapsulation); a sensor with time constant tau cannot resolve a transient faster than tau plus its filter delay, and accuracy computed over stationary data understates error during the excursions a wearer cares about. Observation: the lag, MARD and agreement figures. Inference: that peak height, timing and width on a trace are systematically distorted and that the distortion changes across wear.

Granted tier: PROBABLE, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 4 cited, 4 opened and confirmed

• PROBATION: 1 misquote flag elsewhere in this vector (below the kill line of 2); this axiom's own sources were clean -> capped at PROBABLE
• survived a grounded cross-lab adversary (google vs authors ["anthropic"])
• citations: refetched 89% (>=90%), resolved 97% (>=80%) -> BELOW FLOOR
• dead links: 4 of 35 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED PROBABLE: one of {grounded cross-lab adversary, verified sources} but not both
• CLAMPED: claimed FORGED -> granted PROBABLE (gate lowers, never raises)

S17 (physiological lag), S18 (encapsulation lag), S19 (pivotal accuracy in diabetes), S20 (non-diabetic accuracy).

• S17Basu et al. 2013, Diabetes: time lag of glucose from intravascular to interstitial compartment in humansopened, quote confirmedPhysiological blood-to-interstitial glucose delay about 5 to 6 minutes by tracer in overnight-fasted adults (INTERVENTION, 2013).
• S18McClatchey et al. 2019, Diabetes: fibrotic encapsulation is the dominant source of CGM delaysopened, quote confirmedIn vivo sensors reached maximum current 24 plus or minus 7 minutes after a glucose rise versus 2 plus or minus 1 minutes for blood and 35 seconds in vitro; collagen around the sensor correlated with the delay (R 0.96) (INTERVENTION in mice, 2019).
• S19Garg et al. 2022, Diabetes Technology and Therapeutics: accuracy and safety of Dexcom G7 in adults with diabetesopened, quote confirmed316 adults with diabetes: MARD 8.2 percent arm, 9.1 percent abdomen; 89.6 and 85.5 percent of readings within 15/15; 95.3 and 93.2 percent within 20/20 (controlled clinic comparison, 2022).
• S20J Diabetes Sci Technol, September 2026: agreement of over-the-counter CGMs with capillary-meter glucose in young adults without diabetesopened, quote confirmed39 adults without diabetes: MARD 12.9 percent, bias minus 4.8 mg/dL, 66.5 percent within 15/15, population lag 6.2 minutes; MARD 10.6 to 15.3 percent after sugar versus placebo (controlled comparison against a meter, 2026).

A CGM is an instrument for aggregate and threshold-crossing estimands (mean glucose over days, time above a threshold, nocturnal pattern) and not for the shape or height of a single spike; in a non-diabetic wearer a third of readings sit outside 15/15 of a meter and the spike regime is where agreement is worst. The page's 'continuous glucose monitoring' is bounded to the aggregate use.

A glucose sensor reads interstitial glucose through a growing collagen capsule, so the lag is mostly the sensor's foreign-body response, and in the one opened non-diabetic study about one reading in three sat outside fifteen percent of a meter. Granted PROBABLE, it bounds the page's continuous glucose monitoring to aggregate and threshold quantities over days; 4.6 to A8 add what those aggregates can and cannot predict.

In 16 adults without diabetes on an inpatient unit for 28 days, 27,489 simultaneous readings from two sensors of different brands gave within-subject coefficients of variation of incremental postprandial glucose of 91.7 plus or minus 1.9 and 94.2 plus or minus 2.7 percent, and the two devices ranked the same meals with a mean Kendall tau of 0.43 (S21, 2020; within-person controlled feeding). In 394 healthy adults wearing two sensors for 14 days with 4,457 standardized and 5,738 free meals, two sensors of the same brand agreed on meal ranking at tau 0.87 with incremental-area CV 3.7 percent, while sensors of different brands agreed at tau 0.68 with CV 12.5 percent and misclassified 19 percent of meals between the top and bottom response quintiles (S22, 2022; within-person field design). In 172 adults with type 2 diabetes not on insulin wearing two sensors for two weeks at baseline and three months later, mean glucose between sensors correlated r 0.86 with RMSE 13 mg/dL and time-in-range r 0.88 with RMSE 8 percentage points, and within-person CV of mean glucose across the two periods was 17.4 and 14.2 percent by brand and of time-in-range 20.1 and 18.6 percent (S23, 2023; CORRELATIONAL). Power (MODEL arithmetic from S21): with within-subject CV near 92 percent, resolving a 25 percent difference between two foods in one person needs on the order of 150 to 210 paired exposures per food; a difference near one within-person SD, roughly a doubling, needs about 15 repeats. The only randomized outcome evidence for monitor-guided management is in disease: 175 adults with type 2 diabetes on basal insulin, adjusted HbA1c difference minus 0.4 points (95 percent CI minus 0.8 to minus 0.1) at eight months (S24, 2021; INTERVENTION); none exists in non-diabetic adults. Boundary: the meal-ranking result is from non-diabetic adults; the period-variability result is from type 2 diabetes not on insulin.

The replication unit for a food question is the meal occasion, not the timestamp; dense adjacent readings are autocorrelated and count as far fewer independent observations than their number; when two instruments disagree on ranking, a share of any ranking is the instrument. Observation: the CVs, correlations and the trial effect. Inference: the exposure counts and the non-identifiability claim.

Granted tier: PROBABLE, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 4 cited, 4 opened and confirmed

• PROBATION: 1 misquote flag elsewhere in this vector (below the kill line of 2); this axiom's own sources were clean -> capped at PROBABLE
• survived a grounded cross-lab adversary (google vs authors ["anthropic"])
• citations: refetched 89% (>=90%), resolved 97% (>=80%) -> BELOW FLOOR
• dead links: 4 of 35 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED PROBABLE: one of {grounded cross-lab adversary, verified sources} but not both
• CLAMPED: claimed FORGED -> granted PROBABLE (gate lowers, never raises)

S21 and S22 (dual-sensor meal ranking in non-diabetic adults), S23 (between-sensor and between-period variability of aggregates), S24 (the only randomized utility trial, in insulin-treated type 2 diabetes).

• S21Howard et al. 2020, AJCN: different simultaneous CGMs give discordant meal rankings in subjects without diabetesopened, quote confirmed16 adults without diabetes, 28 inpatient days, 27,489 paired readings: within-subject incremental glucose CV 91.7 and 94.2 percent; meal-ranking Kendall tau 0.43 between devices (within-person controlled feeding, 2020).
• S22AJCN 2022 (ZOE PREDICT 1 secondary analysis): validity of CGM for categorizing glycemic responses to dietopened, quote confirmed394 healthy adults with dual sensors over 14 days, 4,457 standardized and 5,738 free meals: same-brand meal-rank tau 0.87 and iAUC CV 3.7 percent; cross-brand tau 0.68 and CV 12.5 percent; quintile misclassification 5 versus 19 percent (within-person field design, 2022).
• S23Clinical Chemistry 2023: within-person and between-sensor variability in CGM metrics (HYPNOS secondary analysis)opened, quote confirmed172 adults with type 2 diabetes not on insulin wearing two sensors: mean glucose r 0.86 with RMSE 13 mg/dL; time-in-range r 0.88 with RMSE 8 points; within-person CV across two periods three months apart 17.4 and 14.2 percent for mean glucose, 20.1 and 18.6 percent for TIR (CORRELATIONAL, 2023).
• S24MOBILE trial, JAMA 2021: effect of CGM on glycemic control in type 2 diabetes treated with basal insulinopened, quote confirmed175 adults randomized, 8 months: adjusted HbA1c difference minus 0.4 points (95 percent CI minus 0.8 to minus 0.1); the only randomized monitor-guided outcome evidence, in disease (INTERVENTION, 2021).

Single-meal, single-sensor food ranking is refuted in metabolically healthy adults; a before-and-after comparison of mean glucose or time-in-range across two wear periods is read only against about 13 mg/dL and about 8 percentage points of instrument uncertainty plus 14 to 20 percent within-person period variation, so a 10 mg/dL 'improvement' over a quarter is inside the sensor. A food comparison worth running uses one sensor brand, matched conditions and repeated occasions counted as the n.

One meal on one sensor identifies no food effect, because the same meal in the same person varies about as much as its mean and two sensors rank meals differently; the exposure count identifiability needs is on the order of many repeated occasions per food. Granted PROBABLE, it refutes single-meal food ranking and, with 4.8, gives the self-experiment its one admissible sensor design: same brand, matched conditions, repeated occasions counted as the n.

In 50 healthy adults recorded 15 minutes at rest one week apart, heart rate had ICC 0.81 and CV 5.8 percent while RMSSD had ICC 0.75 and CV 29.6 percent (S25, 2025; test-retest). In 41 healthy adults over 14 days of standardized morning chest-strap recordings (424 observations), the within-person CV of RMSSD averaged 0.37 (SD 0.16, range 0.14 to 0.71), and higher RMSSD associated with better self-reported sleep (beta 0.51), lower fatigue (0.28) and lower stress (0.35) with modest effect sizes (S26, 2025; CORRELATIONAL). From a raw-scale CV of 30 percent, MDC95 = 1.96 x sqrt(2) x 30 percent is about 83 percent for a single day and about 31 percent for a seven-day mean under independence, worse with autocorrelation (MODEL arithmetic). Consumer nocturnal HRV against a chest-strap ECG in 13 healthy adults over 536 nights showed limits of agreement of minus 11.4 to plus 6.4 ms for one ring and minus 14.3 to plus 23.6 ms for one watch (S27, 2025; device validation; repeated nights sharpen the estimate for 13 people, not a population). Utility: in a randomized trial of 55 recreationally active adults, HRV-guided training (one-minute supine morning lnRMSSD against a 14-day baseline) produced the same fitness, body-composition and strength gains as predetermined training while completing 12.9 plus or minus 5.6 versus 26.5 plus or minus 2.6 high-intensity days (S28, 2021; INTERVENTION). Boundary: healthy and recreationally active adults; time-domain RMSSD under a fixed posture, window and time of day.

RMSSD differences beat-interval timestamps, so independent timing error of variance sigma squared enters the successive-difference statistic as six sigma squared; respiration rate, posture, time of day, alcohol, illness and recent exertion are inputs to the quantity rather than confounders to adjust away, so the protocol is the measurement. Observation: the ICCs, CVs, limits of agreement and trial counts. Inference: the MDC arithmetic and the many-to-one claim that an RMSSD fall does not identify its cause.

Granted tier: PROBABLE, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 4 cited, 4 opened and confirmed

• PROBATION: 1 misquote flag elsewhere in this vector (below the kill line of 2); this axiom's own sources were clean -> capped at PROBABLE
• survived a grounded cross-lab adversary (google vs authors ["anthropic"])
• citations: refetched 89% (>=90%), resolved 97% (>=80%) -> BELOW FLOOR
• dead links: 4 of 35 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED PROBABLE: one of {grounded cross-lab adversary, verified sources} but not both
• CLAMPED: claimed FORGED -> granted PROBABLE (gate lowers, never raises)

S25 (test-retest ICC and CV), S26 (14-day within-person CV and wellness associations), S27 (consumer device agreement with ECG), S28 (randomized allocation utility).

• S25One-week test-retest recordings of resting cardiorespiratory data for reliability analysis, 2025opened, quote confirmed50 healthy adults, 15-minute resting recordings one week apart: heart rate ICC 0.81 CV 5.8 percent; RMSSD ICC 0.75 CV 29.6 percent (test-retest, 2025).
• S26Associations between daily HRV and self-reported wellness: a 14-day observational study in healthy adults, 2025opened, quote confirmed41 healthy adults, 424 standardized morning observations: within-person RMSSD CV 0.37 (SD 0.16, range 0.14 to 0.71); RMSSD associated with sleep quality beta 0.51, fatigue 0.28, stress 0.35 (CORRELATIONAL, 2025).
• S27Validation of nocturnal resting heart rate and HRV in consumer wearables, 2025opened, quote confirmed13 healthy adults, 536 nights, five devices against a Polar H10 ECG strap: HRV limits of agreement from minus 11.43 to plus 6.43 ms (one ring) to minus 14.30 to plus 23.60 ms (one watch) (device validation, 2025).
• S28High-intensity functional training guided by individualized HRV versus predetermined training, randomized trial, 2021opened, quote confirmed55 recreationally active adults: equal fitness, body-composition and strength gains; HRV-guided group completed 12.9 plus or minus 5.6 versus 26.5 plus or minus 2.6 high-intensity days; one-minute supine morning lnRMSSD against a 14-day baseline (INTERVENTION, 2021).

HRV enters the page as an instrument only as a rolling 7-to-30-day baseline under one device, one metric, one posture and one time relative to waking; a single morning or night number, a cross-person comparison, a device switch mid-series and frequency-domain indices are bounded away. What it has shown it can do is spare hard training days without losing adaptation; it has not shown it predicts aging or illness in healthy adults.

Heart-rate variability under a fixed protocol moves about thirty percent day to day in healthy adults, so a single morning or night has no decision value and a rolling multi-day baseline under one device, one posture and one time relative to waking is the instrument; its one randomized utility is sparing hard training days without losing adaptation. Granted PROBABLE, it keeps HRV on the page only in that bounded form.

Against polysomnography, consumer devices call sleep well and wake poorly: in 34 healthy young adults over three laboratory nights with seven devices, sleep sensitivity was at least 0.93 on every device while wake specificity ranged 0.18 to 0.54, all devices overestimated light sleep and half misclassified deep or REM significantly (S29, 2021); in six wrist wearables, sleep sensitivity exceeded 90 percent with specificity 29.4 to 52.2 percent and kappa 0.21 to 0.53 (S33, 2018); in 98 adults, one watch had sensitivity 95.3 to 95.9 percent, specificity 44.5 to 47.9 percent, kappa 0.43 and a prevalence-and-bias-adjusted kappa of 0.75, which describes a hypothetical balanced night no one sleeps (S31, 2025). Stage agreement: across 11 trackers in 75 adults and 349,114 epochs, four-stage macro-F1 ranged 0.26 to 0.69, with kappa fair (0.2 to 0.4) for two leading wearables and moderate (0.4 to 0.6) for three others (S30, 2023). Pooled across 36 studies of contactless devices, total sleep time was overestimated by 19.55 minutes, deep sleep by 11.07 minutes and wake after onset underestimated by 12.07 minutes (S32, 2023; meta-analysis). The averaging law (MODEL): with true stage proportions pi and the device's confusion matrix C, expected reported proportions are C pi, so more nights make the mean more precise around a biased estimate, and an algorithm update or a change in sleep conditions invalidates any correction. Boundary: healthy and mixed clinical adults in laboratory nights; the asymmetry is worst where wake is the quantity of interest (insomnia, OSA).

The device observes motion and pulse features and infers a 30-second epoch label with no electroencephalogram, so a stage is a classifier output whose errors are systematic (quiet wake looks like sleep; autonomic arousal after alcohol or late exercise looks like absent deep or REM), and systematic error does not average away. Observation: sensitivities, specificities, kappas and minute biases. Inference: the C pi law and the note that observing can perturb the state observed (orthosomnia).

Granted tier: PROBABLE, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 5 cited, 4 opened and confirmed

• PROBATION: 1 misquote flag elsewhere in this vector (below the kill line of 2); this axiom's own sources were clean -> capped at PROBABLE
• survived a grounded cross-lab adversary (google vs authors ["anthropic"])
• citations: refetched 89% (>=90%), resolved 97% (>=80%) -> BELOW FLOOR
• dead links: 4 of 35 source(s) would not open, a miss counted in the ratio above, never a misquote
• EARNED PROBABLE: one of {grounded cross-lab adversary, verified sources} but not both
• CLAMPED: claimed FORGED -> granted PROBABLE (gate lowers, never raises)

S29, S33, S31 (sleep-wake asymmetry and kappa), S30 (multi-device stage agreement), S32 (pooled duration biases).

• S29Chinoy et al. 2021, Sleep: performance of seven consumer sleep-tracking devices compared with polysomnographyopened, quote confirmed34 healthy young adults over three laboratory nights: sleep sensitivity at least 0.93 on every device; wake specificity 0.18 to 0.54; all devices overestimated light sleep; half misclassified deep or REM significantly (device validation, 2021).
• S30Lee et al. 2023, JMIR mHealth: accuracy of 11 wearable, nearable and airable consumer sleep trackersopened, quote confirmed75 adults, 11 devices, 349,114 epochs against PSG: four-stage macro-F1 0.26 to 0.69; kappa fair (0.2 to 0.4) for Apple Watch 8 and Oura Ring 3, moderate (0.4 to 0.6) for three other wearables (device validation, 2023).
• S31Validity and clinical utility of a wrist-worn device against polysomnography, 2025opened, quote confirmed98 adults: sleep sensitivity 95.3 to 95.9 percent, specificity 44.5 to 47.9 percent, kappa 0.43, prevalence-adjusted kappa 0.75; deep sleep overestimated by 14.3 minutes; worse in OSA and insomnia (device validation, 2025).
• S32Contactless consumer sleep-tracking devices versus PSG: systematic review and meta-analysis, 2023opened, quote confirmed22 articles, 36 studies pooled: total sleep time overestimated by 19.55 minutes, deep sleep by 11.07, wake after sleep onset underestimated by 12.07; sleep sensitivity 0.75 to 0.97 (meta-analysis of device validations, 2023).
• S33Biosensors 2018: performance validation of six commercial wrist-worn sleep trackers against polysomnographydid not openSix wrist wearables: sleep sensitivity above 90 percent, wake specificity 29.39 to 52.15 percent, kappa 0.21 to 0.53 (device validation, 2018).

The page's 'sleep staging' as an instrument is bounded to what the devices measure: habitual duration, timing and night-to-night regularity, where two-stage agreement is enough to see an hour's change or a drifting midpoint. Nightly deep-sleep or REM minutes are not a decision variable; stage summaries, if kept, are multi-week relative trends under one device and firmware. A person with insomnia gets the worst of the asymmetry because wake is what the device cannot see.

Consumer sleep staging sees sleep well and wake badly, labels stages at fair-to-moderate agreement with the laboratory, and averaging nights sharpens a biased stage estimate rather than removing the bias; duration, timing and regularity are upheld, nightly deep and REM minutes are refuted. Granted PROBABLE, it is the only sleep axiom this run forged, since the incremental sleep healthspan evidence vector never ran, and it bounds The Physics of Sleep on the instrument side without reopening its architecture claims.

In general-population cohorts the baseline cardiorespiratory fitness gradient is the largest mortality association in exercise epidemiology: high versus low CRF carries an all-cause mortality HR of 0.47 (95% CI 0.39 to 0.56) and each 1-MET higher baseline capacity an HR of 0.83 to 0.89, from an overview of 199 cohorts and 20.9 million observations with certainty graded very low to moderate (S1), consistent with the 2009 pooled RR of 0.87 per MET in healthy adults (S2) and with a referral cohort of 122,007 treadmill-tested patients in which the gradient had no upper limit (S3). That coefficient belongs to a trait, fitness, which integrates genotype, body composition, prior disease and training history. The intervention coefficient is a different and smaller quantity: randomized training in 464 sedentary postmenopausal women raised VO2peak by 4.2, 6.0 and 8.2 percent over six months at rising energy doses (S5), and a two-sample Mendelian randomization study with a VO2max instrument from about 70,000 adults found genetically predicted VO2max had no causal association with longevity or type 2 diabetes once body fat, lean mass and activity were in the model, while those upstream inputs did move VO2max (S4). Law: a per-MET mortality coefficient from a fitness cohort is a prognostic quantity and may not be multiplied by a training-induced MET gain to estimate a mortality effect; the two estimands share a unit and nothing else. Boundary: general-adult and referral cohorts for the gradient; sedentary women for the training gain; the diabetes limb of the MR is contested by a second MR, the longevity limb is not contradicted by any opened source.

VO2max is the Fick product of cardiac output and arteriovenous oxygen difference, so a fitness test reads whole-organism oxygen delivery and extraction, which occult disease, low lean mass and high fat mass depress as surely as training raises it. The trait therefore carries illness and composition signal that a training assignment does not manipulate. Genetic instruments, randomized at conception, separate the two and find the upstream inputs causal and the scoreboard not.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 5 cited, 5 opened and confirmed

• VECTOR KILL: 3 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S1 (2024 overview of cohort meta-analyses, correlational), S2 (2009 meta-analysis, correlational), S3 (2018 referral cohort, correlational), S4 (2025 Mendelian randomization, model class), S5 (2007 randomized dose trial, intervention). Observation: S1, S2, S3, S5 report measurements. Inference: the MR null in S4 is model-class; the anthropic leg reports a second MR with a Fenland instrument finding a causal fitness-to-diabetes path, so the diabetes limb is contested and carried as such. Fetch date 2026-10-05; publication dates as listed.

• S1Lang et al 2024, BJSM: Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among adults, overview of meta-analyses, 199 cohorts, 20.9M observationsopened, quote confirmedHigh vs low CRF all-cause mortality HR 0.47 (0.39 to 0.56); per 1-MET HR 0.89 (0.86 to 0.92) and 0.83 (0.78 to 0.88); certainty very low to moderate; correlational, general adult cohorts, baseline fitness as predictor
• S2Kodama et al 2009, JAMA: Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and womenopened, quote confirmedAll-cause mortality RR 0.87 (0.84 to 0.90) per 1-MET higher exercise capacity; correlational meta-analysis in healthy adults
• S3Mandsager et al 2018, JAMA Network Open: Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testingopened, quote confirmed122,007 referred patients, median 8.4 years: fitness inversely associated with mortality with no upper limit; a referral population, correlational
• S4Kjaergaard et al 2025, JCEM: Cardiorespiratory fitness, body composition, diabetes, and longevity: a 2-sample Mendelian randomization studyopened, quote confirmedGenetically predicted VO2max (N about 70,000) shows no causal association with longevity or T2D; body fat (beta -0.36 per SD), appendicular lean mass (+0.10) and physical activity (+0.29) causally move VO2max; model class
• S5Church et al 2007, JAMA, DREW trial: Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal womenopened, quote confirmed464 women randomized for 6 months: VO2peak +4.2%, +6.0%, +8.2% vs control at rising energy doses; intervention

A page or investigation may state that fitness is the strongest predictor of mortality in cohorts; it may not state or imply that raising fitness by training yields the cohort's per-MET mortality reduction. Fitness testing is a valid instrument for tracking a trainable capacity; its mortality coefficient is not a personal effect size.

Fitness predicts death and training moves fitness, and the two coefficients are not the same number: the cohort gradient is a trait reading of genotype, composition and occult disease, and the one genetic instrument opened found no causal fitness-to-longevity path once body composition and activity were in the model. The whole vector sits at SIGNAL from a vector-level clamp (three misquote flags on sources elsewhere in the exercise dose response and comparison vector), so this law is unanimous across legs and unverified at the gate.

In pooled self-report cohorts (6 cohorts, 661,137 adults, median 14.2 years, 116,686 deaths) all-cause mortality HRs versus no leisure activity were 0.80 below 7.5 MET-h/week, 0.69 at 1 to 2 times the guideline minimum, 0.63 at 2 to 3 times, 0.61 at 3 to 5 times and 0.69 at 10 or more times, with no evidence of harm at the top (S6); a harmonised meta-analysis of non-occupational activity found RR 0.77 at about 75 min/week, 0.69 at 150 and 0.66 at 300 (S7); device-measured quartiles gave HRs 1.00, 0.48, 0.34, 0.27 with the same non-linear shape (S9). Fitting the three Arem bins against log-dose gives roughly a 10 percent lower hazard per doubling of weekly MET-hours (the anthropic leg's arithmetic on S6's published HRs, not the authors' claim). The apparent J or U shape at high volumes is a measurement artifact: in 133,819 health professionals with biennial activity reports, single-baseline or most-recent measures produced a J curve, while cumulative-average activity with a 2-year lag produced a monotone inverse association across 0 to 150 MET-h/week, and the per 10 MET-h/week HR moved from 0.78 (most recent) to 0.87 (cumulative average), so about half the apparent strength of the recent-activity estimate is reverse causation (S8). Law: the mortality association of activity is steepest at the inactive end, flattens in log-dose rather than in minutes, and once prodromal illness is lagged out shows diminishing returns without a demonstrated harmful ceiling in the achievable range. Boundary: middle-aged and older adult cohorts, self-report and device exposure, all-cause mortality, correlational class; the pooled associations are graded only suggestive in an umbrella review (S35).

Each doubling of training load adds a roughly constant increment of physiological reserve (capillary density, stroke volume, insulin sensitivity) while the absolute minutes required double, so the hazard falls with the logarithm of dose. Illness suppresses recent activity before it causes death, which stacks the lowest and recently-reduced bins with dying people and bends the curve; lagging exposure ahead of the risk window removes the bend.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 5 cited, 5 opened and confirmed

• VECTOR KILL: 3 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S6 (2015 pooled cohorts), S7 (2023 harmonised meta-analysis), S8 (2021 lag analysis, the direct test of reverse causation), S9 (2019 device cohorts), S35 (2025 umbrella review grading). Observation: the HRs. Inference: the per-doubling exponent and the attribution of the J shape to reverse causation, which S8 tests directly. Fetch date 2026-10-05.

• S6Arem et al 2015, JAMA Internal Medicine: Leisure time physical activity and mortality, a detailed pooled analysis of the dose-response relationshipopened, quote confirmed6 cohorts, 661,137 adults, median 14.2 years, 116,686 deaths: HR 0.80 below 7.5 MET-h/wk, 0.69 at 1 to 2x, 0.63 at 2 to 3x, 0.61 at 3 to 5x, 0.69 at 10x or more; moderate or vigorous equivalent at matched MET-hours; correlational, self-report
• S7Garcia et al 2023, BJSM: Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes, harmonised meta-analysisopened, quote confirmedAll-cause mortality RR 0.77 (0.73 to 0.80) at about 75 min/wk, 0.69 (0.65 to 0.73) at 150, 0.66 (0.62 to 0.70) at 300; early-event exclusion attenuates; potential impact fraction 15.7% of deaths assuming causality; correlational
• S8Lee et al 2021, Nurses' Health Study and Health Professionals Follow-up Study: Physical activity and all-cause and cause-specific mortality, assessing the impact of reverse causation and measurement erroropened, quote confirmed133,819 participants, 47,273 deaths: per 10 MET-h/wk HR 0.95 baseline, 0.78 simple-updated, 0.87 cumulative-average; a 2-year lag removes most reverse causation; cumulative average shows a monotone inverse association to 150 MET-h/wk and no J-curve; correlational
• S9Ekelund et al 2019, BMJ: Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality, harmonised meta-analysisopened, quote confirmed8 cohorts, n=36,383, mean age 62.6, median 5.8 years, 2,149 deaths: total activity quartile HRs 1.00, 0.48, 0.34, 0.27 (0.23 to 0.32); light activity 0.38 and MVPA 0.52 in the top quartile; non-linear; correlational, device-measured
• S35Umbrella review 2025, Journal of Cachexia, Sarcopenia and Muscle: Associations between exercise training, physical activity, sedentary behaviour and mortalityopened, quote confirmedExercise and activity mortality associations graded only suggestive, not highly suggestive or convincing; correlational

The gain to state is the inactivity-to-activity transition; a page may say more activity is associated with lower mortality with diminishing returns, and may not state a volume above which activity harms, since no lagged cohort shows one. For a person already active, the marginal mortality association of added volume is small and undetectable in one body.

The activity-mortality association is concave in log-dose, steepest at the inactive end, and the apparent harm at high volume disappears when exposure is lagged ahead of prodromal illness; for an already-active person the marginal association of added volume is small and undetectable in one body. SIGNAL by the vector-level clamp, not by dissent.

Self-reported leisure activity in pooled cohorts gives a maximum all-cause mortality reduction of about 30 to 40 percent (HR 0.61 to 0.69 at the plateau in 661,137 adults, S6; RR 0.66 at 300 min/week, S7), while accelerometer-measured total activity in a harmonised meta-analysis of 8 cohorts (n=36,383, mean age 62.6, median 5.8 years, 2,149 deaths) gives HR 0.27 (0.23 to 0.32) for the most active versus least active quarter, with light activity alone at HR 0.38 and MVPA at 0.52 (S9). The device estimate is not the truth either: a 7-day wear window captures current activity, which prodromal illness depresses, and the lag analysis in 133,819 adults shows recent-activity measures carry the largest reverse-causation inflation (per 10 MET-h/week HR 0.78 most-recent versus 0.87 cumulative-average, S8). Self-report dilutes the slope through misclassification; device measurement sharpens it and imports illness signal; early-event exclusion attenuates both (S7). Law: the measured size of the activity-mortality association varies about twofold with the exposure instrument and the lag applied, so a single hazard ratio for exercise is an instrument-and-design statement, never a biological constant, and the true causal effect plausibly lies between half the observational estimate and the estimate itself. Boundary: middle-aged and older adult cohorts, all-cause mortality, correlational class; no opened source measures dilution and reverse causation in the same cohort.

Regression dilution: random error in a self-reported exposure flattens the fitted slope toward null. Reverse causation: a 7-day device window measures the organism's current state, and a dying organism moves less, which steepens the slope beyond the causal effect. The two biases pull in opposite directions and neither has been removed in the same dataset.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed PROBABLE) · Survived the adversary's attack · Sources: 4 cited, 4 opened and confirmed

• VECTOR KILL: 3 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed PROBABLE -> granted SIGNAL (gate lowers, never raises)

S6 and S7 (self-report plateaus), S9 (device quartiles, abstract read 2026-10-05), S8 (lag test of reverse causation). Observation: the HRs by instrument. Inference: attribution of the gap to dilution and reverse causation; S8 measures the reverse-causation component, the dilution component is inferred. Publication dates 2015, 2023, 2019, 2021.

• S6Arem et al 2015, JAMA Internal Medicine: Leisure time physical activity and mortality, a detailed pooled analysis of the dose-response relationshipopened, quote confirmed6 cohorts, 661,137 adults, median 14.2 years, 116,686 deaths: HR 0.80 below 7.5 MET-h/wk, 0.69 at 1 to 2x, 0.63 at 2 to 3x, 0.61 at 3 to 5x, 0.69 at 10x or more; moderate or vigorous equivalent at matched MET-hours; correlational, self-report
• S7Garcia et al 2023, BJSM: Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes, harmonised meta-analysisopened, quote confirmedAll-cause mortality RR 0.77 (0.73 to 0.80) at about 75 min/wk, 0.69 (0.65 to 0.73) at 150, 0.66 (0.62 to 0.70) at 300; early-event exclusion attenuates; potential impact fraction 15.7% of deaths assuming causality; correlational
• S8Lee et al 2021, Nurses' Health Study and Health Professionals Follow-up Study: Physical activity and all-cause and cause-specific mortality, assessing the impact of reverse causation and measurement erroropened, quote confirmed133,819 participants, 47,273 deaths: per 10 MET-h/wk HR 0.95 baseline, 0.78 simple-updated, 0.87 cumulative-average; a 2-year lag removes most reverse causation; cumulative average shows a monotone inverse association to 150 MET-h/wk and no J-curve; correlational
• S9Ekelund et al 2019, BMJ: Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality, harmonised meta-analysisopened, quote confirmed8 cohorts, n=36,383, mean age 62.6, median 5.8 years, 2,149 deaths: total activity quartile HRs 1.00, 0.48, 0.34, 0.27 (0.23 to 0.32); light activity 0.38 and MVPA 0.52 in the top quartile; non-linear; correlational, device-measured

A page that quotes one mortality percentage for exercise must name the instrument and lag behind it; the defensible plain-language claim is that the association is real, large at the inactive end and of uncertain exact size.

The size of the exercise effect is a property of the exposure instrument: self-report dilutes the slope, a seven-day device window imports illness signal and about doubles it, and no dataset has removed both biases at once. Read with the instrument validity and utility vector, it is the population-scale version of the run's measurement law: the instrument is part of the estimand.

In the LIFE trial, 1,635 sedentary adults aged 70 to 89 with functional limitation randomized to structured moderate activity versus health education had major mobility disability (inability to walk 400 m) in 30.1 versus 35.5 percent over a mean 2.6 years, HR 0.82 (0.69 to 0.98), and persistent disability HR 0.72 (0.57 to 0.91) (S12). In Generation 100, 1,567 Norwegian adults aged 70 to 77 randomized to five years of HIIT, moderate continuous training or guideline advice showed no all-cause mortality difference between control (4.7 percent) and the combined exercise arms, with HIIT HR 0.63 (0.33 to 1.20) and MICT HR 1.24 (0.73 to 2.10), controls who exercised at an intensity between the arms, 87.5 percent good baseline health and five-year survival above the national average (S10, S11). Lifestyle arms of diabetes-prevention trials did not move all-cause mortality at 21 years (DPPOS lifestyle HR 1.02, 0.81 to 1.28, 453 deaths, S14) or the cardiovascular composite at 9.6 years (Look AHEAD HR 0.95, 0.83 to 1.09, S15); the one long-run lifestyle mortality result, Da Qing's pooled diet and exercise arms at 30 years, HR 0.74 (0.61 to 0.89), does not isolate exercise (S16). Across the randomized literature 14,716 participants have been randomized to exercise in 57 mortality trials against more than 300,000 in drug trials (S19). Law: a trial of healthy volunteers accrues too few deaths to detect the 10 to 20 percent hazard difference cohorts predict for a realistic dose contrast (about 70 deaths in 1,567 people over five years detects a halving, not a fifth), while disability endpoints accrue hundreds of events in the same population, so exercise's demonstrated causal domain is function and its mortality effect is estimated from cohorts, not shown in trials. Boundary: older adults in trials; function and mortality endpoints; intervention class.

Statistical power scales with the number of events, not participants. Healthy volunteers who can be randomized to exercise have low baseline hazard, and exercise cannot be blinded or placebo-controlled, so the control arm exercises too and the contrast shrinks. Mobility loss is common and fast in the frail-but-ambulatory, death is rare and slow, so the same trial resolves one endpoint and not the other.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 8 cited, 8 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S17 (number_not_on_page) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S12 (2014 RCT, function), S10 and S11 (2020 RCT, mortality primary, abstract read 2026-10-05), S14 (2021, 21-year mortality), S15 (2013), S16 (2019), S13 (2002 parent trial), S19 (2013 randomized-participant counts). Observation: all trial figures. Inference: the event-count arithmetic and the claim that the gap is structural.

• S10Stensvold et al 2020, BMJ, Generation 100: Effect of exercise training for five years on all cause mortality in older adults, randomised controlled trialopened, quote confirmed1,567 adults aged 70 to 77, 5 years, all-cause mortality primary: control 4.7%, HIIT HR 0.63 (0.33 to 1.20), MICT HR 1.24 (0.73 to 2.10), HIIT vs MICT HR 0.51 (0.25 to 1.02); controls exercised at an intensity between the arms; 87.5% good baseline health; intervention
• S11NTNU CERG, Generation 100 investigator pageopened, quote confirmedInvestigator summary: 3% died in the HIIT group, 5.9% in the moderate group, not statistically significant; healthy-participant selection; argument class, supports S10
• S12Pahor et al 2014, JAMA, LIFE study: Effect of structured physical activity on prevention of major mobility disability in older adults, randomized clinical trialopened, quote confirmed1,635 adults aged 70 to 89 with functional limitation, mean 2.6 years: major mobility disability 30.1% vs 35.5%, HR 0.82 (0.69 to 0.98); persistent disability HR 0.72 (0.57 to 0.91); intervention
• S13Diabetes Prevention Program Research Group 2002, NEJM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metforminopened, quote confirmed3,234 adults with impaired glucose regulation, mean 2.8 years: lifestyle reduced incident diabetes 58%, metformin 31%, vs placebo; intervention, matched population and endpoint
• S14Lee CG et al 2021, Diabetes Care: Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and DPP Outcomes Studyopened, quote confirmedMedian 21 years, 453 deaths: metformin all-cause mortality HR 0.99 (0.79 to 1.25); lifestyle HR 1.02 (0.81 to 1.28); intervention
• S15Look AHEAD Research Group 2013, NEJM: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetesopened, quote confirmed5,145 overweight or obese adults with T2D, median 9.6 years: cardiovascular composite HR 0.95 (0.83 to 1.09); intervention
• S16Gong et al 2019, Lancet Diabetes & Endocrinology: Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance, 30-year results of the Da Qing studyopened, quote confirmedPooled diet and exercise arms, 30 years: all-cause mortality HR 0.74 (0.61 to 0.89); does not isolate exercise; intervention
• S19Naci and Ioannidis 2013, BMJ: Comparative effectiveness of exercise and drug interventions on mortality outcomes, metaepidemiological studyopened, quote confirmed305 RCTs, 339,274 participants, 14,716 randomized to exercise in 57 trials: no detectable exercise vs drug mortality difference in CHD secondary prevention or prediabetes; exercise better than anticoagulants (OR 0.09) and antiplatelets (OR 0.10) after stroke; diuretics better than exercise in heart failure (OR 4.11); network meta-analysis of RCTs

A page may claim that structured exercise prevents loss of mobility in older adults as a randomized result; it may not claim a randomized lifespan effect of exercise in humans. The honest frame for an exercise program is healthspan engineering with a plausible, cohort-estimated, unproven lifespan externality.

Randomized exercise has one healthspan demonstration, mobility disability in older adults with functional limitation, and no mortality demonstration, and the gap is structural because deaths are rare in volunteers who can be randomized to exercise while disability is common. With 1.5 and A6 it fixes the honest comparator for the not-exotic claim: neither the ordinary levers nor the exotic ones have a randomized lifespan result in healthy humans. The gate's tripwire on one source and the vector-level clamp hold it at SIGNAL.

The label does not denote one exposure: Seiler's three-zone model places zone 2 between the first and second ventilatory thresholds in elite endurance athletes (S33), while popular use places it below the first threshold, so a heart-rate percentage, a lactate band and a threshold-anchored domain are different interventions. On adaptation, a within-subject single-leg trial in 10 young men found six sessions of interval training over two weeks produced greater increases in citrate synthase activity and mitochondrial respiration than continuous training matched for total work and duration (S34), and a 2025 narrative review reports AMPK and PGC-1alpha activation scaling with intensity and small, inconsistent activation after moderate continuous work (S32), so the claim that sub-threshold work uniquely maximizes mitochondrial adaptation is contradicted at the signaling level in young men. On mortality, self-report cohorts find the guideline minimum met by moderate or vigorous activity associated with near-maximal benefit at matched MET-hours (S6), device cohorts find any intensity associated with lower mortality (S9), and the only randomized intensity contrast with all-cause mortality as the declared primary endpoint, Generation 100, had the moderate continuous arm (about 70 percent of peak heart rate) numerically worst of three (5.9 percent deaths; MICT HR 1.24, 0.73 to 2.10 versus control; HIIT versus MICT HR 0.51, 0.25 to 1.02), underpowered and with a contaminated control (S10, S11). Law: no opened source isolates a sub-threshold continuous prescription and shows a mortality advantage; total dose, not its intensity distribution, carries the verified association; and the single randomized datum is unfavorable to the moderate arm without refuting it. Boundary: athletes for the definition, young men for the adaptation result, older adults for the trial, adult cohorts for the associations; blog-sourced fold-change figures quoted by one leg are excluded.

Mitochondrial biogenesis is triggered by cellular energy stress (ATP turnover, AMP accumulation, calcium flux) whose magnitude rises with intensity; low-intensity work earns its place through low fatigue cost per minute, which lets volume accumulate, not through a privileged signal. Mortality cohorts measure volume in MET-hours and cannot resolve an intensity-distribution hypothesis.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 7 cited, 7 opened and confirmed

• VECTOR KILL: 3 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S33 (2006 athlete observation), S34 (2017 within-subject intervention, abstract read 2026-10-05), S32 (2025 narrative review, argument class), S6 and S9 (cohorts), S10 and S11 (2020 RCT). Observation: S6, S9, S10, S34 figures. Inference: the signaling mechanism via S32.

• S6Arem et al 2015, JAMA Internal Medicine: Leisure time physical activity and mortality, a detailed pooled analysis of the dose-response relationshipopened, quote confirmed6 cohorts, 661,137 adults, median 14.2 years, 116,686 deaths: HR 0.80 below 7.5 MET-h/wk, 0.69 at 1 to 2x, 0.63 at 2 to 3x, 0.61 at 3 to 5x, 0.69 at 10x or more; moderate or vigorous equivalent at matched MET-hours; correlational, self-report
• S9Ekelund et al 2019, BMJ: Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality, harmonised meta-analysisopened, quote confirmed8 cohorts, n=36,383, mean age 62.6, median 5.8 years, 2,149 deaths: total activity quartile HRs 1.00, 0.48, 0.34, 0.27 (0.23 to 0.32); light activity 0.38 and MVPA 0.52 in the top quartile; non-linear; correlational, device-measured
• S10Stensvold et al 2020, BMJ, Generation 100: Effect of exercise training for five years on all cause mortality in older adults, randomised controlled trialopened, quote confirmed1,567 adults aged 70 to 77, 5 years, all-cause mortality primary: control 4.7%, HIIT HR 0.63 (0.33 to 1.20), MICT HR 1.24 (0.73 to 2.10), HIIT vs MICT HR 0.51 (0.25 to 1.02); controls exercised at an intensity between the arms; 87.5% good baseline health; intervention
• S11NTNU CERG, Generation 100 investigator pageopened, quote confirmedInvestigator summary: 3% died in the HIIT group, 5.9% in the moderate group, not statistically significant; healthy-participant selection; argument class, supports S10
• S32Storoschuk et al 2025, Sports Medicine: Much Ado About Zone 2, narrative reviewopened, quote confirmedAMPK and PGC-1alpha activation scale with exercise intensity; moderate continuous work shows small, inconsistent activation in human studies; narrative review, argument class
• S33Seiler and Kjerland 2006, Scandinavian Journal of Medicine & Science in Sports: Quantifying training intensity distribution in elite endurance athletes, is there evidence for an optimal distribution?opened, quote confirmedThe three-zone model places zone 2 between the first and second ventilatory thresholds in elite endurance athletes, so the label is not portable across definitions; correlational athlete observation
• S34MacInnis et al 2017, Journal of Physiology: Superior mitochondrial adaptations in human skeletal muscle after interval compared to continuous single-leg cycling matched for total workopened, quote confirmed10 young men, within-subject single-leg design, 6 sessions over 2 weeks: interval training produced greater increases in citrate synthase activity and mitochondrial respiration than work- and duration-matched continuous training; intervention

The page may keep aerobic volume as a lever; it may not name zone 2 as a lever with a demonstrated longevity benefit distinct from other intensities, and should not imply intensity below threshold is uniquely protective. A self-experimenter can test intensity against fitness and lactate-power endpoints, never against mortality.

Zone 2 is not one exposure, the signaling that drives mitochondrial adaptation scales with intensity rather than favoring sub-threshold work, mortality cohorts measure volume not intensity, and the single randomized intensity contrast with a mortality endpoint ran numerically against the moderate arm without power to refute it. The page's lever resolves to aerobic volume at any intensity; the gate holds it at SIGNAL by the vector-level clamp.

In 42 cohort studies of 3,002,203 community-dwelling adults, lowest versus highest grip strength carried all-cause mortality HR 1.41 (1.30 to 1.52) and each 5 kg decrease HR 1.16 (1.12 to 1.20), linear to 56 kg and surviving exclusion of baseline cardiovascular disease and cancer (S27); within PURE's 155,722 adults, low grip strength carried a mortality population attributable fraction of 11.6 percent (7.3 to 16.0) against 2.2 percent for low physical activity (S22). Muscle-strengthening activity, the behavior, is associated with 10 to 17 percent lower all-cause mortality in 16 cohorts, J-shaped with the maximum around 30 to 60 minutes a week and unclear at higher volumes (S26). On the intervention side, progressive resistance training in 121 trials of older adults produced a large effect on strength and a smaller effect on physical function (S28), protein supplementation augments those strength and lean-mass gains with no mortality endpoint (S29), combined training adds CRF and lean mass over aerobic training alone in CAD patients without changing biomarkers (S39), and the anthropic leg's extract reports grip strength predicting mortality more strongly (HR 0.69) than the more trainable, more load-bearing knee extension (HR 0.86) in about 2 million adults, the tell that the grip gradient carries disease signal. No resistance-training trial with all-cause mortality as a primary endpoint was found by any leg. Law: the grip gradient is a marker of neuromuscular integrity, nutrition and occult disease and cannot be converted into a lifting prescription; the behavior's association is modest and J-shaped in minutes; the only demonstrated causal effects of resistance training are on strength, lean mass and, less strongly, function. Boundary: community-dwelling and older adults; mortality is correlational, strength and function are intervention class.

Grip force is cheap to measure and falls with sarcopenia, catabolic illness, inflammation and malnutrition, which is why it predicts death well and why the prediction is not a training target. Resistance training raises force through neural recruitment and hypertrophy; transfer to function is partial because function depends on power, balance and task demand (power equals force times velocity), so strength gains outrun functional gains.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed PROBABLE) · Refuted by the adversary on a source said less than the claim · Sources: 6 cited, 6 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S20 (number_not_on_page) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed PROBABLE -> granted SIGNAL (gate lowers, never raises)

S27 (2017 grip meta-analysis, abstract read 2026-10-05), S22 (2020 PURE PAFs), S26 (2022 behavior cohorts), S28 (2009 Cochrane trials), S29 (2018 protein meta-analysis), S39 (2024 CAD RCT meta-analysis). Observation: all HRs and trial effects. Inference: the marker reading of the grip gradient; the knee-extension contrast is a single-leg extract and holds the tier at PROBABLE.

• S22Yusuf et al 2020, Lancet, PURE: Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 countriesopened, quote confirmedWithin-cohort mortality population attributable fractions: low physical activity 2.2% (1.0 to 3.3), low grip strength 11.6% (7.3 to 16.0), poor diet 11.1% (7.7 to 14.6), hypertension 8.8% (7.6 to 9.9); sleep not assessed; correlational
• S26Momma et al 2022, BJSM: Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases, systematic review and meta-analysis of cohort studiesopened, quote confirmed16 cohort studies: muscle-strengthening activity associated with 10 to 17% lower all-cause mortality, CVD, cancer and diabetes; J-shaped with maximum about 10 to 20% at about 30 to 60 min/week; higher volumes unclear; correlational
• S27Wu et al 2017, JAMDA: Association of grip strength with risk of all-cause mortality, cardiovascular diseases, and cancer in community-dwelling populations, meta-analysis of prospective cohortsopened, quote confirmed42 studies, 3,002,203 participants: lowest vs highest grip HR 1.41 (1.30 to 1.52) for all-cause mortality; per 5 kg decrease HR 1.16 (1.12 to 1.20); linear to 56 kg; survives exclusion of baseline CVD and cancer; correlational
• S28Liu and Latham 2009, Cochrane Database of Systematic Reviews: Progressive resistance strength training for improving physical function in older adultsopened, quote confirmed121 trials: large effect on strength, smaller effect on physical function; intervention
• S29Morton et al 2018, BJSM: Systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strengthopened, quote confirmedProtein supplementation augments resistance-training gains in strength and lean mass; no mortality endpoint; intervention
• S39Terada et al 2024, BJSM: Effects of muscle strength training combined with aerobic training versus aerobic training alone on cardiovascular disease risk indicators in patients with coronary artery disease, meta-analysis of RCTsopened, quote confirmed23 RCTs, N=916 CAD patients: combined training vs aerobic alone SMD 0.26 (0.02 to 0.49) for CRF, +0.78 kg lean body mass, -2.2% body fat, no difference in cardiometabolic biomarkers; meta-analysis of RCTs

The page may keep strength as a lever for function and independence, framed as a randomized strength-and-function result plus a cohort mortality association; it may not quote grip-strength mortality figures as the benefit of lifting, and may not state a mortality effect of resistance training as demonstrated.

Strength is two variables: a grip gradient that reads illness and nutrition and predicts death well, and a trainable capacity whose demonstrated effects are strength, lean mass and, less strongly, function, with no randomized mortality test. With 4.3 it bounds two of the page's six levers (strength, protein) to training adaptation; a tripwire and the vector-level clamp hold it at SIGNAL.

A cross-lever comparison requires the same endpoint, the same population and baseline hazard, the same follow-up, a commensurable exposure contrast and the same evidence class. The matched exceptions that exist: in a network meta-analysis of 305 RCTs with 339,274 participants (14,716 in 57 exercise trials), exercise and drug interventions showed no detectable mortality difference in secondary prevention of coronary heart disease and in prediabetes, exercise beat anticoagulants (OR 0.09) and antiplatelets (OR 0.10) after stroke, and diuretics beat exercise in heart failure (OR 4.11) (S19); in the DPP, lifestyle cut incident diabetes 58 percent and metformin 31 percent in the same 3,234 adults over 2.8 years, and neither moved all-cause mortality over 21 years (S13, S14). The unmatched pairs that are routinely ranked anyway: an exercise cohort RR of 0.69 at 150 min/week (S7) against SPRINT's randomized all-cause mortality HR 0.73 in 9,361 hypertensive adults over 3.26 years (S18), SELECT's HR 0.81 in 17,604 adults with established cardiovascular disease over 34 months (S20), or statins' RR 0.90 against placebo across 55 trials (S21); and the SPAN cohort's HR 0.36 for optimal sleep, activity and diet tertiles in 59,078 adults over 8.1 years (S30) against any drug trial. Those pairs differ in design, baseline hazard (several-fold), follow-up, blinding and contrast, so the drug's randomized demonstration is a statement about its trial and not about biology ranking above exercise, and the cohort's larger ratio is a statement about healthy-volunteer selection and compounding habits and not about biology ranking above the drug; within SPRINT itself survival improved while gait speed and mobility did not (S37), and in PREDIMED a cardiovascular composite HR of about 0.70 sat beside an all-cause mortality HR of 0.98 (0.77 to 1.24) in the same older high-risk Spanish adults (S17), so even endpoints inside one trial are not interchangeable. Law: a demonstrated effect and a large association are different quantities; two levers are comparable only when all five conditions hold, and absent that the honest output is a joint description with the mismatches named. Boundary: secondary-prevention and high-risk populations for the matched RCT comparisons; healthy cohorts for the associations.

A hazard ratio is a within-study contrast between two arms of one population under one design; it carries that population's baseline hazard, that design's biases and that follow-up's time-to-effect. Transporting it beside another study's ratio multiplies the two sets of unmatched terms. Pharmacology buys randomized mortality demonstrations with high-hazard populations, large samples and placebo blinding, none of which exercise can have.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a source said less than the claim · Sources: 10 cited, 8 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S17 (number_not_on_page), S20 (number_not_on_page) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S19 (2013 network meta-analysis of RCTs, abstract read 2026-10-05), S13 and S14 (2002, 2021), S7 (2023 cohort), S18 (2015 RCT), S20 (2023 RCT), S21 (2020 RCT meta-analysis), S30 (2025 cohort), S37 (2017 RCT secondary analysis), S17 (2018 RCT, composite versus all-cause endpoints). Observation: all effect sizes. Inference: the five conditions and the noncomparability verdict.

• S7Garcia et al 2023, BJSM: Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes, harmonised meta-analysisopened, quote confirmedAll-cause mortality RR 0.77 (0.73 to 0.80) at about 75 min/wk, 0.69 (0.65 to 0.73) at 150, 0.66 (0.62 to 0.70) at 300; early-event exclusion attenuates; potential impact fraction 15.7% of deaths assuming causality; correlational
• S13Diabetes Prevention Program Research Group 2002, NEJM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metforminopened, quote confirmed3,234 adults with impaired glucose regulation, mean 2.8 years: lifestyle reduced incident diabetes 58%, metformin 31%, vs placebo; intervention, matched population and endpoint
• S14Lee CG et al 2021, Diabetes Care: Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and DPP Outcomes Studyopened, quote confirmedMedian 21 years, 453 deaths: metformin all-cause mortality HR 0.99 (0.79 to 1.25); lifestyle HR 1.02 (0.81 to 1.28); intervention
• S17Estruch et al 2018, NEJM, PREDIMED revised analysis: Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nutsopened, the number was not on the pageOlder Spanish adults at high cardiovascular risk, median 4.8 years: cardiovascular composite HR about 0.70; all-cause mortality HR 0.98 (0.77 to 1.24); intervention
• S18SPRINT Research Group 2015, NEJM: A randomized trial of intensive versus standard blood-pressure controlopened, quote confirmed9,361 adults with elevated blood pressure and raised cardiovascular risk, no diabetes, median 3.26 years: all-cause mortality HR 0.73 (0.60 to 0.90); intervention in a selected high-risk population
• S19Naci and Ioannidis 2013, BMJ: Comparative effectiveness of exercise and drug interventions on mortality outcomes, metaepidemiological studyopened, quote confirmed305 RCTs, 339,274 participants, 14,716 randomized to exercise in 57 trials: no detectable exercise vs drug mortality difference in CHD secondary prevention or prediabetes; exercise better than anticoagulants (OR 0.09) and antiplatelets (OR 0.10) after stroke; diuretics better than exercise in heart failure (OR 4.11); network meta-analysis of RCTs
• S20Lincoff et al 2023, NEJM, SELECT: Semaglutide and cardiovascular outcomes in obesity without diabetesopened, the number was not on the page17,604 adults with overweight or obesity and established cardiovascular disease, mean 34 months: MACE HR 0.80 (0.72 to 0.90); all-cause mortality HR 0.81 (0.71 to 0.93); intervention in a high-hazard population
• S21All-cause mortality and cardiovascular death between statins and omega-3 supplementation: a meta-analysis and network meta-analysis of 55 RCTs (2020)opened, quote confirmedStatins vs placebo all-cause mortality RR 0.90 (0.86 to 0.94); CVD death RR 0.86 (0.80 to 0.92); meta-analysis of RCTs
• S30Koemel et al 2025, BMC Medicine, UK Biobank SPAN: Minimum and optimal combined variations in sleep, physical activity, and nutrition in relation to all-cause mortality riskopened, quote confirmed59,078 adults, median age 64, 8.1 years, 2,458 deaths: optimal joint tertiles (sleep 7.2 to 8.0 h, MVPA 42 to 103 min/day, diet score 57.5 to 72.5) HR 0.36 (0.26 to 0.50) vs lowest tertiles; minimum combined increase of 15 min sleep, 1.6 min MVPA, 5 diet points HR 0.90 (0.88 to 0.93); device-measured; correlational
• S37Odden et al 2017: Intensive blood pressure control, gait speed, and mobility limitation, the Systolic Blood Pressure Intervention Trialopened, quote confirmedIntensive blood pressure control did not improve gait speed or mobility limitation in older SPRINT participants despite the parent trial's mortality benefit; survival and function are not interchangeable endpoints; intervention secondary analysis

The page may not state or imply that the non-exotic levers out-perform pharmacology, nor that pharmacology out-performs them; it may state that in matched randomized comparisons exercise and drugs are often similar on mortality in secondary prevention, and that lifestyle and drug effects are measured on different populations and cannot be summed or ranked.

Levers may be ranked only inside one design, population, endpoint and follow-up, and in the few matched randomized comparisons exercise and drugs trade places by condition; the big cohort ratios and the drug trials cannot be set beside one another. This is 1.8's tuple rule applied to ranking, and it is why the page's not-exotic sentence may describe where the burden sits and may not rank ordinary levers above or below pharmacology.

The only defensible cross-lever share comparisons are within one framework. In PURE (155,722 adults, 21 countries, median about 9.5 years) the mortality population attributable fractions were poor diet 11.1 percent (7.7 to 14.6), low grip strength 11.6 percent (7.3 to 16.0), hypertension 8.8 percent (7.6 to 9.9) and low physical activity 2.2 percent (1.0 to 3.3), with sleep not assessed (S22). In GBD 2021, dietary risks were attributed about 8 million deaths, high fasting plasma glucose 5.4 million and low physical activity 0.686 million (ranked 14th), with high systolic blood pressure, smoking and glucose the top three risks (S23); GBD 2019 attributed 2.4 million deaths to alcohol and 10.8 million to high systolic blood pressure and treated sugar-sweetened beverages, not sugar, as the dietary component (S24). A different counterfactual gives a different number for the same exposure: Garcia's potential impact fraction of 15.7 percent of deaths if all cohort members met the activity minimum, assuming causality (S7), against GBD's roughly 1 percent, with a rival 7.2 percent all-cause share for inactivity reported in the anthropic leg, a spread driven by how mediation through blood pressure, adiposity and glucose is assigned and by GBD version instability (S25). Combined-lever cohorts show compounding: in UK Biobank SPAN, optimal joint tertiles of device-measured sleep (7.2 to 8.0 h), MVPA (42 to 103 min/day) and diet quality carried HR 0.36 (0.26 to 0.50) versus the lowest tertiles, and a minimum combined shift of 15 min sleep, 1.6 min MVPA and 5 diet points HR 0.90 (0.88 to 0.93) (S30), with about 9.35 lifespan-years and 9.45 healthspan-years between jointly favourable and unfavourable tertiles (S31); joint activity-and-sleep associations are nonlinear and interacting (S38), and sleep alone enters the ledgers only as a correlational U-curve versus 7 hours (RR 1.07, 1.04, 1.01 at 4, 5, 6 h; 1.07, 1.21, 1.37, 1.55 at 8 to 11 h) whose claims The Physics of Sleep holds and the incremental sleep healthspan evidence vector sizes (S36). Law: the share of mortality the non-exotic exposures carry is a modeled quantity that ranges several-fold with the counterfactual and the mediation rule; within any one ledger inactivity sits below diet, blood pressure, smoking and glycemia; and the joint cohort association of the levers is far larger than any single lever's, with no demonstrated additive or causal decomposition. Boundary: adult cohorts and global burden models; attributable fractions and hazard ratios are correlational and model class, not trial effects; the ledgers test sugar-sweetened beverages and heavy drinking, not 'no sugar' or 'no alcohol'.

A population attributable fraction multiplies relative risk by exposure prevalence under a chosen counterfactual, so a common exposure with a modest risk ratio (poor diet) outranks a rarer or weaker one (inactivity), and a hierarchical model that routes activity's effect through blood pressure and glucose credits those downstream risks. People who sleep, move and eat well cluster on wealth, health and absence of illness, so joint-tertile contrasts in cohorts capture compounding habits and healthy-volunteer selection together.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a source said less than the claim · Sources: 9 cited, 7 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S20 (number_not_on_page), S23 (number_not_on_page) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S22 (2020 PURE), S23 (2024 GBD 2021), S24 (2020 GBD 2019), S25 (2026-03-13 GBD instability), S7 (2023 potential impact fraction), S30 (2025 SPAN, abstract read 2026-10-05), S31 (2025 lifespan and healthspan), S38 (UK Biobank joint cohort), S36 (2016 sleep dose-response meta-analysis). Observation: PAFs, attributable deaths and HRs. Inference: the mediation explanation of the spread and the non-additivity.

• S7Garcia et al 2023, BJSM: Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes, harmonised meta-analysisopened, quote confirmedAll-cause mortality RR 0.77 (0.73 to 0.80) at about 75 min/wk, 0.69 (0.65 to 0.73) at 150, 0.66 (0.62 to 0.70) at 300; early-event exclusion attenuates; potential impact fraction 15.7% of deaths assuming causality; correlational
• S22Yusuf et al 2020, Lancet, PURE: Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 countriesopened, quote confirmedWithin-cohort mortality population attributable fractions: low physical activity 2.2% (1.0 to 3.3), low grip strength 11.6% (7.3 to 16.0), poor diet 11.1% (7.7 to 14.6), hypertension 8.8% (7.6 to 9.9); sleep not assessed; correlational
• S23GBD 2021 Risk Factors Collaborators 2024, Lancet: Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990 to 2021opened, the number was not on the page2021 attributable deaths: dietary risks about 8 million, high fasting plasma glucose 5.4 million, low physical activity 0.686 million (ranked 14th); high systolic blood pressure, smoking and glucose the top three; model class
• S24GBD 2019 Risk Factors Collaborators 2020, Lancet: Global burden of 87 risk factors in 204 countries and territories, 1990 to 2019opened, quote confirmed2019 attributable deaths: dietary risks about 8 million, alcohol use 2.4 million, high systolic blood pressure 10.8 million; sugar-sweetened beverages a separate dietary component; model class
• S25JAMA Health Forum, published 2026-03-13: changes in attributable-burden estimates across Global Burden of Disease roundsopened, quote confirmedLarge changes in attributable-burden estimates across GBD versions, with low physical activity among the less stable categories; model class
• S30Koemel et al 2025, BMC Medicine, UK Biobank SPAN: Minimum and optimal combined variations in sleep, physical activity, and nutrition in relation to all-cause mortality riskopened, quote confirmed59,078 adults, median age 64, 8.1 years, 2,458 deaths: optimal joint tertiles (sleep 7.2 to 8.0 h, MVPA 42 to 103 min/day, diet score 57.5 to 72.5) HR 0.36 (0.26 to 0.50) vs lowest tertiles; minimum combined increase of 15 min sleep, 1.6 min MVPA, 5 diet points HR 0.90 (0.88 to 0.93); device-measured; correlational
• S31Koemel et al 2025, eClinicalMedicine: Minimum combined sleep, physical activity, and nutrition variations associated with lifespan and healthspan improvements, population cohort studyopened, quote confirmedAbout 9.35 additional lifespan-years and 9.45 healthspan-years for jointly favourable vs unfavourable sleep, MVPA and diet tertiles in UK Biobank; correlational
• S36Shen et al 2016, Scientific Reports: Nighttime sleep duration, 24-hour sleep duration and risk of all-cause mortality among adults, meta-analysis of prospective cohort studiesopened, quote confirmedVersus 7 h: RR 1.07, 1.04, 1.01 at 4, 5, 6 h and 1.07, 1.21, 1.37, 1.55 at 8, 9, 10, 11 h of nighttime sleep; U-shaped with a steeper long-sleep limb; correlational
• S38UK Biobank: Joint association of physical activity and sleep duration with risk of all-cause and cause-specific mortality, accelerometry cohortdid not open92,221 device-monitored participants, median 7 years: nonlinear joint associations and interactions between activity and sleep duration on mortality; no substitution claim; correlational

The page may state that the levers it names carry a large share of attributable mortality in cohort ledgers and that combined favourable habits are associated with about a 64 percent lower mortality hazard and about nine more life-years in one cohort; it may not state a number for 'most', may not put exercise first, and should note that blood pressure, smoking and glycemia, absent from the six levers, outrank inactivity on every ledger.

On any one burden ledger the ordinary exposures carry a large but mediation-sensitive share of mortality, inactivity sits below diet, blood pressure, smoking and glycemia, and the ledgers test sugar-sweetened drinks and heavy drinking rather than the page's words no sugar and no alcohol. With 4.1, it names the levers the page omits (energy balance, blood pressure, smoking, glycemia) that outrank several it names; two tripwires and the vector-level clamp hold it at SIGNAL.

In healthy non-obese adults aged 21 to 50 (CALERIE 2, 218 randomized, 2 years, INTERVENTION), a prescribed 25 percent calorie restriction that achieved 11.9 percent produced about 10 percent weight loss (71 percent of it fat) and lowered LDL cholesterol, total-to-HDL ratio, systolic and diastolic blood pressure, C-reactive protein and improved an insulin-sensitivity index; the panel changes held after adjustment for the weight change itself. In adults with obesity (Magkos 2016, 40 randomized to weight maintenance or progressive loss, INTERVENTION), about 5 percent weight loss improved insulin sensitivity in adipose tissue, liver and muscle together and cut intrahepatic fat, with further gains at 11 and 16 percent. The surplus itself is set by food form more than by label arithmetic: in 20 inpatient adults fed ultra-processed and unprocessed diets matched for presented calories, sugar, fat, sodium, fibre and macronutrients for 14 days each in random order (Hall 2019, INTERVENTION crossover), ad libitum intake ran about 500 kcal/day higher on the ultra-processed diet (+280 from carbohydrate, +230 from fat, -2 from protein) and weight moved +0.9 versus -0.9 kg, correlation of weight change with energy intake r = 0.8, meals eaten at 48 versus 31 kcal/min. Boundary: the CALERIE population was non-obese and young-to-middle-aged; the Magkos population had obesity; the Hall crossover was 14 days per arm in a ward. The mechanism from surplus to insulin resistance (subcutaneous overflow, ectopic lipid, diacylglycerol-activated kinase blockade of insulin signalling) is MODEL and review grade in these legs, not measured here.

Fat mass is the time integral of intake minus expenditure (conservation, an accounting identity that explains nothing about why either term changed). Once subcutaneous adipose storage is exceeded, lipid is deposited in liver, muscle and pancreas; ectopic lipid intermediates impair insulin signalling and raise hepatic VLDL output; this is the shared trunk through which protein surplus, liquid sugar and ethanol reach lipids and, last, glycaemia. Reversing the surplus reverses the ectopic store first, which is why 5 percent loss already moves three tissues' insulin sensitivity.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a source said less than the claim · Sources: 4 cited, 3 opened and confirmed

• VECTOR KILL: 2 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S21 (CALERIE 2, 218 adults, INTERVENTION, published 2019, opened 2026-10-04 by the anthropic leg at snippet level); S3 (Magkos 2016, 40 adults with obesity, INTERVENTION, opened by the openai leg); S22 (Hall 2019, 20 inpatients, INTERVENTION crossover, anthropic leg); S2 (OmniHeart, the stable-weight control that shows composition can also move lipids without this lever). Observation: the panel changes, the kcal/day difference, the weight changes. Inference: the overflow-to-ectopic-lipid chain.

• S21CALERIE 2, 2019, Lancet Diabetes and Endocrinology: 218 healthy non-obese adults aged 21 to 50, 2 yearsopened, quote confirmed11.9 percent restriction achieved, about 10 percent weight loss; LDL, total-to-HDL, blood pressure, CRP and insulin sensitivity improved, robust to adjustment for weight change
• S3Magkos 2016, Cell Metabolism: 40 adults with obesity, progressive weight loss (mirror PDF)opened, quote confirmedAbout 5 percent weight loss improved adipose, liver and muscle insulin sensitivity and cut liver fat
• S22Hall 2019, Cell Metabolism: 20 inpatient adults, ultra-processed versus unprocessed, 14 days eachdid not openAbout 500 kcal/day more eaten on the ultra-processed diet at matched label nutrients; +0.9 versus -0.9 kg; r = 0.8 weight with intake; 48 versus 31 kcal/min
• S2OmniHeart 2005, JAMA: 164 adults, controlled-feeding crossover at stable weightopened, quote confirmedReplacing carbohydrate with protein or unsaturated fat at stable weight lowered blood pressure and moved lipids; composition acts without weight loss

When the health page sizes levers, energy balance and body-fat distribution is the one nutrition lever with a two-year randomized panel result in healthy adults; "protein, no alcohol, no sugar" are each smaller and partly routed through it. A page that names six levers and omits energy balance has left out the largest nutrition term; the page may keep "most of longevity is not exotic" only if the unnamed lever is admitted.

Energy balance stored past subcutaneous capacity is the nutrition lever with a two-year randomized panel result in healthy adults and a ward crossover showing food form alone shifts intake, and the page's protein, no sugar and no alcohol act partly through it; the page's six-lever list omits the largest nutrition term. The whole vector is SIGNAL by a vector-level clamp (two misquote flags, on sources used by A5 and A6), so this unanimous law is unverified at the gate rather than contested.

In OmniHeart (164 adults with prehypertension or stage 1 hypertension, three controlled-feeding diets in randomized crossover at stable weight, INTERVENTION, 2005), replacing about 10 percent of energy from carbohydrate with protein lowered LDL cholesterol and triglycerides and blood pressure, and replacing it with unsaturated fat lowered blood pressure and triglycerides and raised HDL, all without weight change. In Bray 2012 (25 healthy adults overfed about 40 percent above requirement for 8 weeks at 5, 15 or 25 percent protein, INTERVENTION), fat gain was the same across arms (about 3.5 kg) while lean mass and energy expenditure rose only in the 15 and 25 percent arms and fell in the 5 percent arm; the scale would have misread the result. In Te Morenga 2012 (systematic review of trials in adults, INTERVENTION synthesis), reducing dietary sugars in ad libitum diets lowered body weight by 0.80 kg (95 percent CI 0.39 to 1.21, 5 trials) while isoenergetic exchange of sugars for other carbohydrates produced no weight change. Boundary: these are weeks-to-months surrogate endpoints (lipids, blood pressure, body composition), in prehypertensive, healthy or overweight adults; none is a hard-outcome trial.

At fixed energy, raising one macronutrient lowers another, so the exposure is always a pair (what came in, what left); the lipid and pressure responses in OmniHeart arise from the displaced carbohydrate as much as from the added protein or fat. Under surplus, protein's amino acids are partitioned to lean tissue and to thermogenesis rather than sparing fat storage, which is why fat gain matched across arms. Under ad libitum eating, removing sugar works mainly by removing energy; under isoenergetic exchange it does not, which separates the energy channel from any composition channel.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 3 cited, 3 opened and confirmed

• VECTOR KILL: 2 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S2 (OmniHeart 2005, 164 adults, randomized crossover controlled feeding, openai leg); S1 (Bray 2012, 25 adults, parallel overfeeding, openai leg); S5 (Te Morenga 2012, trial synthesis, openai leg). Observation: the lipid, pressure and body-composition differences. Inference: that the displaced nutrient is part of the cause.

• S2OmniHeart 2005, JAMA: 164 adults, controlled-feeding crossover at stable weightopened, quote confirmedReplacing carbohydrate with protein or unsaturated fat at stable weight lowered blood pressure and moved lipids; composition acts without weight loss
• S1Bray 2012, JAMA: protein during 8-week overfeeding, 25 adultsopened, quote confirmedFat gain equal across 5/15/25 percent protein arms while lean mass and expenditure differed; protein under surplus partitions, it does not spare fat
• S5Te Morenga 2012, BMJ: dietary sugars and body weight, trial synthesisopened, quote confirmedReducing sugars in ad libitum diets lowered weight 0.80 kg; isoenergetic exchange for other carbohydrate changed weight not at all

The page's "protein" and "no sugar" each need an "instead of what" before they can be sized: protein replacing refined carbohydrate at stable weight has a measured lipid and pressure effect; protein stacked on a surplus does not spare fat gain; sugar removed from an ad libitum diet drops weight by under a kilogram on average; sugar swapped for starch at equal energy changes weight not at all.

Every nutrient effect is a substitution at a stated energy level, so protein and no sugar need an instead-of-what before they are claims: protein replacing refined carbohydrate at stable weight has a measured lipid and pressure effect, sugar removed from an ad libitum diet works through energy and swapped for starch does nothing. It is the nutrition version of 1.8's tuple rule.

In Morton 2018 (meta-analysis and meta-regression of 49 randomized trials, 1,863 healthy adults doing resistance training, INTERVENTION synthesis), protein supplementation added about 0.30 kg of fat-free mass (and 2.49 kg to one-repetition maximum) over training alone, and the regression breakpoint beyond which more protein added no fat-free mass sat at 1.62 g/kg/day with a 95 percent confidence interval reaching about 2.2 g/kg/day; the effect fell with age and rose with training experience. In an acute feeding meta-analysis (Wolever 2024, controlled feeding trials in adults without diabetes, INTERVENTION synthesis), adding protein to a carbohydrate meal lowered the postprandial glucose area and raised the insulin area, a glucose-lowering mechanism that is not evidence of improved insulin sensitivity. The only outcome-adjacent evidence against surplus is CORRELATIONAL: in NHANES III (Levine 2014, 6,381 adults 50 and over followed about 18 years), adults aged 50 to 65 in the high-protein group (20 percent or more of energy) had a hazard ratio of 4.33 for cancer mortality versus the low-protein group (under 10 percent), and the association reversed after 65, where higher protein tracked lower mortality; this is one cohort, one diet recall, and it has not been reproduced by a trial. Boundary: the plateau is measured in trained adults in energy balance; the requirement rises in energy deficit and in older adults with anabolic resistance; no trial measures protein against all-cause mortality or disability.

Muscle protein synthesis saturates with amino-acid delivery because the stimulus is mechanical loading, not substrate; above the saturating dose, amino acids are deaminated and oxidized or converted to glucose, so surplus is an occupied energy slot rather than more tissue. Requirement-type nutrients therefore show a steep response below adequacy and a flat one above, the opposite shape from a toxin.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 4 cited, 3 opened and confirmed

• VECTOR KILL: 2 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S4 (Morton 2018, 49 RCTs, openai and anthropic legs); S16 (Wolever 2024, exa leg); S14 (Levine 2014, NHANES III cohort, gemini leg; CORRELATIONAL, single leg); S1 (Bray 2012, partitioning under surplus). Observation: the 0.30 kg, the breakpoint, the glucose and insulin areas, the hazard ratio. Inference: saturation as the shape.

• S4Morton 2018, BJSM: 49 RCTs, 1,863 resistance-training adults (PDF mirror)opened, quote confirmedProtein supplementation adds about 0.30 kg fat-free mass; no further gain above 1.62 g/kg/day (CI to about 2.2)
• S16Wolever 2024, Journal of Nutrition: acute controlled feeding trials, protein added to carbohydratedid not openAdding protein to a carbohydrate meal lowers glucose area and raises insulin area in adults without diabetes
• S14Levine 2014, Cell Metabolism: NHANES III, 6,381 adults 50 and overopened, quote confirmedHigh protein at ages 50 to 65 HR 4.33 for cancer mortality versus low protein; reversal after 65; correlational
• S1Bray 2012, JAMA: protein during 8-week overfeeding, 25 adultsopened, quote confirmedFat gain equal across 5/15/25 percent protein arms while lean mass and expenditure differed; protein under surplus partitions, it does not spare fat

The page may keep "protein" as a lever only in the adequacy sense (reaching the plateau, especially when training or in a deficit); it may not present protein as a dose that scales with longevity, because the lean-mass yield above the plateau is nil and the only mortality data points the other way at midlife and is correlational.

Protein is a threshold nutrient: in resistance-trained adults the lean-mass yield plateaus near the dose the meta-regression found and the whole supplementation effect is fractions of a kilogram, and no trial links protein above adequacy to longer life while the one midlife cohort points the other way. With 3.6 it bounds the page's protein lever to adequacy in training, not a dose that scales with longevity.

In Geidl-Flueck 2021 (94 healthy men, randomized to 80 g/day of fructose-, sucrose- or glucose-sweetened beverage or abstinence for 7 weeks, INTERVENTION), basal hepatic fatty-acid synthesis roughly doubled in the fructose and sucrose arms and did not change in the glucose arm, with reported total energy intake similar across arms; this is a flux measurement, not a liver-fat stock or an outcome. In Maersk 2012 (47 overweight adults randomized to 1 L/day of sucrose cola, isocaloric semi-skim milk, aspartame cola or water for 6 months, INTERVENTION, magnetic resonance spectroscopy), the sucrose drink raised liver, muscle and visceral fat relative to the isocaloric milk, so the form of the energy, not its amount, set the depot. In REDUCS (Campos 2015, 31 overweight adults drinking at least 660 mL/day of sugar-sweetened beverage, 12 weeks of replacement with artificially sweetened drinks, INTERVENTION), intrahepatocellular lipid fell to 74 percent of baseline, the fall concentrated in those above 60 mmol/L at baseline, with no change in body weight, visceral fat or other metabolic markers. "Added sugars" is a labelling category (sugars added in processing plus syrups, honey and concentrated juices, per the FDA label rule), not a molecule the liver detects; the biochemical category is fructose fraction and delivery rate. Boundary: healthy or overweight adults, liquid sugar at 80 g/day or about 1 L/day, 7 weeks to 6 months, liver-fat and lipid-flux endpoints; the opened legs carried no trial of added sugar against a hard outcome, and the observational link runs through ultra-processed food (an umbrella review of 39 meta-analyses rates diabetes and obesity associations as highly suggestive, CORRELATIONAL), which does not isolate sugar from energy density and matrix.

Fructose is cleared on first pass by the liver and enters glycolysis below the phosphofructokinase control point, so its flux is not fed back by cellular energy state; the carbon is pushed to de novo lipogenesis and VLDL export or stored as liver fat. Glucose at the same dose is regulated and distributed to muscle. Liquid delivery raises the rate, and the lipogenic response steepens where hepatic oxidative capacity is exceeded, which is why benefit concentrates in high-dose consumers with existing steatosis and is near zero at low baseline intake.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Refuted by the adversary on a claim no opened source could verify · Sources: 5 cited, 1 opened and confirmed

• VECTOR KILL: 2 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S6 (Geidl-Flueck 2021, 94 men, INTERVENTION; openai and anthropic legs); S23 (Maersk 2012, 47 adults, INTERVENTION; anthropic leg, snippet level); S24 (REDUCS 2015, 31 adults, INTERVENTION; anthropic leg, snippet level); S8 (FDA added-sugars definition, regulatory text; openai leg); S25 (ultra-processed umbrella review 2024, CORRELATIONAL; exa leg). Observation: the synthesis rates, the depot changes, the 74 percent. Inference: the phosphofructokinase bypass as the reason.

• S6Geidl-Flueck 2021, Journal of Hepatology: 94 healthy men, 7 weeks, 80 g/day sugar beveragesdid not openFructose and sucrose roughly doubled basal hepatic fatty-acid synthesis; glucose did not; energy intake similar across arms
• S23Maersk 2012, AJCN: 47 overweight adults, 1 L/day sucrose cola, isocaloric milk, diet cola or water, 6 monthsdid not openSucrose drink raised liver, muscle and visceral fat relative to isocaloric milk; the form of energy set the depot
• S24REDUCS, Campos 2015, Obesity: 31 overweight adults drinking at least 660 mL/day sugar-sweetened beverage, 12 weeks replacementdid not openLiver fat fell to 74 percent of baseline, concentrated above 60 mmol/L baseline; no change in weight, visceral fat or other markers
• S8FDA: added sugars on the Nutrition Facts labelopened, quote confirmedAdded sugars is a labelling category (processing sugars, syrups, honey, concentrated juices), not a biochemical one
• S25Umbrella review 2024, Clinical Nutrition: 39 meta-analyses of ultra-processed fooddid not openDiabetes, overweight and obesity associations rated highly suggestive; observational; does not isolate sugar from energy density and matrix

The page may keep "no sugar" only as "no sweetened drinks and little added fructose", sized as a liver-fat lever whose yield depends on the starting dose; it may not present sugar avoidance as a glucose-trace lever or as a uniformly large term, and whole fruit and lactose are outside the opened evidence.

The exposure behind no sugar is hepatic fructose load, chiefly from sweetened drinks: at matched energy fructose and sucrose raise liver fat synthesis and glucose does not, and removing the drink lowers liver fat mainly in heavy consumers with existing liver fat, without moving weight. It is a liver-fat and lipid lever, not a glucose-trace lever, which is why a sensor (2.5, 4.6) is the wrong instrument for it.

In Zhao 2023 (107 cohort studies, 4,838,825 participants, 425,564 deaths, CORRELATIONAL synthesis with prespecified bias adjustments), the relative risk of all-cause mortality for 1.3 to under 25 g/day of ethanol versus lifetime non-drinkers was 0.93 (95 percent CI 0.85 to 1.01), and for 45 to under 65 g/day 1.19 (1.07 to 1.32), rising further above that. In Stockwell 2024 (the same 107 cohorts analysed by study quality), cohorts with mean age 55 or under, follow-up past 55 and former and occasional drinkers removed from the reference group gave RR 0.98 (0.87 to 1.11) for low-volume drinkers, while lower-quality cohorts gave 0.84 (0.79 to 0.89); among non-smoking cohorts the mean low-volume RR was 1.16 (0.91 to 1.41). The Sarich 2024 umbrella review of reviews using lifetime abstainers or low-volume drinkers as reference reached the same shape. A MESA re-analysis (CORRELATIONAL) found that removing former drinkers fixes the abstainer side but not survivorship among current drinkers, and correcting both shifted light drinking toward harm and gave a dose response with coronary artery calcium. In the China Kadoorie Biobank (Millwood 2019, about 512,000 adults, Mendelian randomization on ALDH2 and ADH1B variants, MODEL-grade instrument), genotype-predicted alcohol intake raised blood pressure and stroke risk with no protective range, and gave no clear effect on myocardial infarction. Boundary: mortality and cardiovascular endpoints in middle-aged and older cohorts; the genetic evidence is East Asian; no randomized trial of moderate drinking has been completed.

Ethanol is a pharmacological exposure and an energy substrate at once: it is oxidized preferentially through acetaldehyde and acetate, shifting hepatic redox toward fat synthesis and away from fat oxidation, and it raises blood pressure; none of this has a dose below which the mechanism switches off. The apparent benefit arises in the data, not the body: sick quitters inflate the reference group's mortality, and survivors among heavy drinkers deflate the high-dose harm.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 6 cited, 4 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S27 (misquote) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S7 (Zhao 2023, openai leg); S18 (Stockwell 2024, exa leg); S19 (Sarich 2024, exa leg); S27 (MESA re-analysis, anthropic leg, snippet level); S9 (Millwood 2019 China Kadoorie MR, mirror PDF opened by the openai leg); S10 (NIAAA review of ethanol metabolism, mechanism only). Observation: the relative risks and intervals, the genotype associations. Inference: that the J is manufactured by selection.

• S7Zhao 2023, JAMA Network Open: 107 cohorts, 4,838,825 participants, 425,564 deathsopened, quote confirmedLow-volume drinking RR 0.93 (0.85 to 1.01) versus lifetime non-drinkers; 45 to 65 g/day RR 1.19 (1.07 to 1.32)
• S18Stockwell 2024, J Stud Alcohol Drugs: 107 cohorts analysed by study quality (PDF mirror)opened, quote confirmedHigher-quality cohorts RR 0.98 (0.87 to 1.11) for low-volume drinkers; lower-quality 0.84 (0.79 to 0.89); non-smoking cohorts 1.16 (0.91 to 1.41)
• S19Sarich 2024, Addiction: umbrella review with lifetime-abstainer or low-volume referencedid not openReviews with clean reference groups show no J-shape; risk rises with consumption
• S27MESA re-analysis 2022, European Journal of Preventive Cardiology: alcohol, abstainer bias and survivorshipmisquoteRemoving former drinkers fixes the abstainer side only; correcting survivorship shifts light drinking toward harm with a dose response in coronary calcium
• S9Millwood 2019, Lancet: China Kadoorie Biobank Mendelian randomization, about 512,000 adults (mirror PDF)opened, quote confirmedGenotype-predicted alcohol intake raised blood pressure and stroke with no protective range; no clear effect on myocardial infarction
• S10NIAAA Alcohol Research: ethanol metabolism reviewopened, quote confirmedEthanol oxidation through acetaldehyde and acetate shifts hepatic redox toward fat synthesis; mechanism not represented by a glucose trace

The page may keep "no alcohol" as a lever in direction; it should size it honestly: the measured harm is at and above about 25 g/day and climbs with dose, the difference between zero and very occasional drinking sits inside the confidence interval of no difference, and the claim rests on corrected cohorts and genetic instruments with no trial.

Alcohol's protective dose is a reference-group artifact: with former and occasional drinkers out of the abstainer group low-volume drinking shows no protection, harm rises with dose from the middle of the range, and genetic instruments show harm to blood pressure and stroke with no cardioprotection; the zero-versus-occasional difference sits inside the interval of no difference and no trial exists. The gate's tripwire fired on this axiom's own use of one source, so it is SIGNAL on its own account as well as by the vector-level clamp.

In Hall 2021 (20 adults without diabetes, inpatient randomized crossover, two weeks each on a low-fat plant-based diet and a ketogenic diet, INTERVENTION), the higher-carbohydrate diet produced higher postprandial glucose and insulin yet participants ate about 689 kcal/day less on it than on the ketogenic diet, so the flatter trace sat on the diet with the higher spontaneous intake. In OmniHeart (164 adults, controlled feeding at stable weight, INTERVENTION) lipids and blood pressure moved under substitution with no weight change and no glucose endpoint driving it; in Bray 2012 (25 adults, INTERVENTION) fat gain was identical while the scale and lean mass diverged. In Hjort 2024 (systematic review of 71 studies of glucose variability in people without diabetes, mostly cross-sectional, CORRELATIONAL; searches to April 2022), variability was higher in prediabetes and associated with beta-cell dysfunction, while its relations to insulin sensitivity, adiposity, fatty liver, lipids and blood pressure were inconsistent or absent. Apolipoprotein B is prioritized as the lipid determinant of coronary disease in multivariable Mendelian randomization (MODEL-grade instrument), and the chain from surplus, liquid fructose and ethanol to atherosclerosis runs through liver fat, hepatic insulin resistance and VLDL-apoB output, not through meal glucose amplitude. The lipid rise under carbohydrate restriction in lean people ("lean mass hyper-responder") was carried by one leg from secondary pages only and rides here as a flag, not a measurement. Boundary: healthy, prehypertensive and obese adults; surrogate endpoints over days to months; the ordering of the chain is inferred from mechanism and from cross-sectional data, which is why this axiom claims PROBABLE and not FORGED.

Beta-cell compensation holds glucose near normal for years while adiposity, ectopic liver fat, hepatic insulin resistance and particle output are already moving; glucose becomes abnormal only after compensation fails. An instrument reading the terminal node therefore has the longest lag and the weakest link to the levers; the proximal nodes (intake, liver fat, apoB, fasting insulin) are measurable earlier and move first.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed PROBABLE) · Survived the adversary's attack · Sources: 6 cited, 5 opened and confirmed

• TRIPWIRE: this axiom's own source(s) S30 (misquote) were wrong -> SIGNAL (the tripwire hits the axiom whose use of a source was wrong)
• CLAMPED: claimed PROBABLE -> granted SIGNAL (gate lowers, never raises)

S15 (Hall 2021, 20 adults, INTERVENTION crossover; openai leg); S2 (OmniHeart; openai leg); S1 (Bray 2012; openai leg); S11 (Hjort 2024, 71 studies, CORRELATIONAL; openai leg); S30 (apoB multivariable MR, MODEL; anthropic leg, snippet level); S3 (Magkos 2016, insulin sensitivity moved by 5 percent weight loss, INTERVENTION). Observation: the 689 kcal/day, the lipid changes at stable weight, the Hjort associations. Inference: the ordering of the chain and the lag.

• S15Hall 2021, Nature Medicine: 20 inpatient adults without diabetes, randomized crossover (PDF mirror)opened, quote confirmedHigher-carbohydrate diet gave higher glucose and insulin excursions yet about 689 kcal/day lower spontaneous intake than the ketogenic diet
• S2OmniHeart 2005, JAMA: 164 adults, controlled-feeding crossover at stable weightopened, quote confirmedReplacing carbohydrate with protein or unsaturated fat at stable weight lowered blood pressure and moved lipids; composition acts without weight loss
• S1Bray 2012, JAMA: protein during 8-week overfeeding, 25 adultsopened, quote confirmedFat gain equal across 5/15/25 percent protein arms while lean mass and expenditure differed; protein under surplus partitions, it does not spare fat
• S11Hjort 2024: systematic review, 71 studies of glucose variability in people without diabetesopened, quote confirmedNon-diabetic glucose variability tracks beta-cell dysfunction; relations to insulin sensitivity, adiposity, liver fat, lipids and blood pressure inconsistent
• S30Multivariable Mendelian randomization 2020, PLoS Medicine: apolipoprotein B and coronary diseasemisquoteApoB prioritized as the lipid determinant of coronary disease; diet reaches atherosclerosis through particle output, not meal glucose
• S3Magkos 2016, Cell Metabolism: 40 adults with obesity, progressive weight loss (mirror PDF)opened, quote confirmedAbout 5 percent weight loss improved adipose, liver and muscle insulin sensitivity and cut liver fat

The page may keep continuous glucose monitoring as an instrument only with the bound that it reads the most lagged node; the sentence "the question is what does the data say" needs the clause "which data", because the glucose data can say "flat" while intake, liver fat and apoB say otherwise, and those three are the earlier readings.

Glycaemia is the last node to move in the diet-to-disease chain, so a flat sensor trace does not certify metabolic health: the flatter trace in one inpatient crossover sat on the diet with the higher spontaneous intake, lipids move at stable weight with no glucose endpoint driving them, and non-diabetic variability indexes beta-cell function rather than the levers. It gives the page's what does the data say its missing clause, which data; the tripwire fired on this axiom's own source, so SIGNAL on its own account.

The outcome evidence attaches to slow variability measured in laboratories across years: in CARDIA (young adults followed about 30 years, CORRELATIONAL), each 1 SD higher average real variability of fasting glucose before any diabetes carried hazard ratios of 1.64 for incident diabetes, 1.15 for cardiovascular disease and 1.25 for all-cause mortality after adjustment; in a 2017 cohort of adults without diabetes (CORRELATIONAL), the highest versus lowest quartile of visit-to-visit fasting glucose variability carried a hazard ratio of 1.55 for all-cause mortality; in a Korean national cohort of about 3.2 million adults (CORRELATIONAL), the highest variability quartile carried hazard ratios of 1.08 for myocardial infarction, 1.09 for stroke and 1.12 for death. A 14-day sensor coefficient of variation is a fast response variable set by meal composition, timing and the preceding exercise bout; in Hjort 2024 (71 studies, CORRELATIONAL) non-diabetic sensor variability tracked beta-cell function and was not consistently related to the other risk factors, and the leg that searched found no cohort linking sensor-derived variability in healthy adults to hard outcomes. The nearest result is GluFormer (published 14 January 2026, MODEL): a representation learned from sensor traces of 10,812 adults, mostly without diabetes, predicted incident diabetes and cardiovascular mortality in the AEGIS cohort (580 adults, median 11 years of follow-up) better than HbA1c, with most events in the top predicted-risk quartile; it evaluates a learned pattern in a cohort not shown to be uniformly normoglycaemic, not the causal weight of variability itself. In ZOE PREDICT (adults without diabetes, CORRELATIONAL, company-funded preprint) sensor variability associated with diet and lifestyle; in 53 non-diabetic and 52 pre-diabetic Indian adults over 14 days (CORRELATIONAL) sensor metrics separated the two groups. Boundary: the hazard ratios belong to the laboratory estimand in middle-aged cohorts and transfer to no sensor metric; the sensor estimand has association and one prognostic model, no outcome cohort in healthy adults.

Variability across annual fasting draws indexes a drifting state of the person (beta-cell reserve, weight trajectory, illness, medication) and so forecasts the person's trajectory; variability across a fortnight of meals indexes the meals and the day before. A forecasting variable can carry outcome signal while being causally inert, so prediction, where it exists, says nothing about whether suppressing the excursion helps.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 7 cited, 5 opened and confirmed

• VECTOR KILL: 2 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S28 (CARDIA, Diabetes Care 2019; anthropic leg, snippet level); S26 (JAHA 2017 cohort; gemini leg); S29 (Korean national cohort; anthropic leg, snippet level); S11 (Hjort 2024; openai leg); S12 (GluFormer, Nature, 14 January 2026, abstract opened live by the openai leg); S20 (Berry 2023 PREDICT preprint; exa leg); S34 (Chaudhry 2024, 105 adults, 14 days; exa leg). Observation: the hazard ratios, the AEGIC prediction result, the group separation. Inference: that the two variabilities are different quantities.

• S28CARDIA 2019, Diabetes Care: visit-to-visit glycaemic variability over 30 yearsdid not openPer 1 SD of fasting-glucose variability before diabetes: HR 1.64 diabetes, 1.15 cardiovascular disease, 1.25 all-cause mortality
• S26JAHA 2017: visit-to-visit fasting glucose variability and all-cause mortality in adults without diabetesdid not openHighest versus lowest quartile HR 1.55 for all-cause mortality; a years-scale laboratory estimand, not a sensor metric
• S29Korean national cohort 2019, Medicine: about 3.2 million adults, long-term glycaemic variabilityopened, quote confirmedHighest variability quartile HR 1.08 myocardial infarction, 1.09 stroke, 1.12 all-cause death
• S11Hjort 2024: systematic review, 71 studies of glucose variability in people without diabetesopened, quote confirmedNon-diabetic glucose variability tracks beta-cell dysfunction; relations to insulin sensitivity, adiposity, liver fat, lipids and blood pressure inconsistent
• S12GluFormer, Nature, 14 January 2026: 10,812 adults' sensor traces; AEGIS 580 adults, median 11 yearsopened, quote confirmedA learned sensor representation predicted incident diabetes and cardiovascular mortality better than HbA1c; a learned pattern, not isolated variability
• S20Berry 2023 preprint, ZOE PREDICT: glycaemic variability in people without diabetesopened, quote confirmedSensor variability associates with diet, lifestyle and health; association only; company-funded
• S34Chaudhry 2024, Scientific Reports: 53 non-diabetic and 52 pre-diabetic Indian adults, 14 daysopened, quote confirmedSensor metrics separate non-diabetic from pre-diabetic adults; association only

The page may say a glucose monitor is an instrument that reads a real signal (meal response and, through learned patterns, some prognostic information); it may not borrow the 1.12 to 1.55 mortality hazard ratios of the laboratory estimand to justify flattening a fortnight's trace, and a self-experimenter should treat the sensor's coefficient of variation as a food log, not a risk score.

Glucose variability predicts outcomes is true for years-scale visit-to-visit laboratory fasting glucose and unproven for a fortnight of sensor variability in healthy adults; the two are different physical quantities sharing a word, and the one sensor-based prognostic result is a learned pattern in a mixed cohort. It is 3.1's prediction-is-not-a-lever law applied to the page's sensor.

In Richardson 2024 (systematic review and meta-analysis of 25 randomized trials of sensor feedback for behaviour change, INTERVENTION synthesis), 17 trials were in type 2 diabetes, 3 in type 1, 3 in gestational diabetes and 3 in obesity; pooled feedback lowered HbA1c by 0.28 percentage points and raised time in range by 7.4 percentage points, with no significant effect on BMI and a pooled weight change of -0.7 kg across 8 studies (I-squared 0 percent); only 4 of 25 trials measured dietary change and 5 of 25 physical activity. A 2026 review restricted to people without diabetes (UNVERIFIED live fetch; the anthropic leg verified it at snippet level only) reported that sensor use may lower mean glucose versus control but did not change BMI or glycaemic variability, and that in subgroup analysis the glycaemic benefit appeared in prediabetes and not in normoglycaemic adults. In the ZOE METHOD trial (347 general adults, 18 weeks, INTERVENTION), a personalized programme that bundled sensor data with microbiome and other inputs, education and an app improved triglycerides, weight and HbA1c and did not change LDL; contact and intensity were not matched, so the sensor's share is unidentified. The one non-diabetic eating-pattern result opened is exploratory (17 postmenopausal women with obesity, 16 weeks, a secondary analysis). The Diabetes Prevention Program lowered incident diabetes by 58 percent over about three years in high-risk adults with a lifestyle programme and no sensor, which fixes the comparator any sensor claim must beat. The leg that searched found no trial comparing sensor feedback against food logging or daily weighing at matched contact. Boundary: adults with diabetes, prediabetes, obesity or general adults in programmes; glycaemic and weight surrogates over 12 to 24 weeks; no trial in normoglycaemic adults with a disease, disability or mortality endpoint, and no trial isolating glucose information from attention.

A sensor changes behaviour through salience and immediacy of feedback, a channel any self-monitoring instrument can occupy; in a person whose glucose is already normal the feedback has little to correct, so the target metric barely moves and whatever benefit appears must travel through intake and adherence, not glycaemia. Identifying the sensor's own effect requires randomizing the information while holding the diet and the coaching fixed, which no opened trial did.

Granted tier: SIGNAL, set by the code gate on October 4, 2026 (the writer claimed FORGED) · Survived the adversary's attack · Sources: 6 cited, 6 opened and confirmed

• VECTOR KILL: 2 misquote flag(s) in this vector (>= 2) -> SIGNAL for every axiom in it
• CLAMPED: claimed FORGED -> granted SIGNAL (gate lowers, never raises)

S17 (Richardson 2024, 25 RCTs; exa and anthropic legs); S32 (Eur J Med Res 2026 non-diabetic review; anthropic leg; UNVERIFIED live fetch); S13 (ZOE METHOD 2024, 347 adults; openai leg); S33 (Jospe 2024, 17 women; exa leg); S31 (DPP, 58 percent; openai leg); S15 (Hall 2021, the flatter trace on the higher-intake diet). Observation: the pooled differences, the subgroup null, the trial counts. Inference: the adherence channel as the mechanism.

• S17Richardson 2024, IJBNPA: 25 RCTs of sensor feedback as a behaviour-change toolopened, quote confirmed17 of 25 trials in type 2 diabetes, 3 in obesity; HbA1c -0.28 points, time in range +7.4 points, weight -0.7 kg across 8 studies, BMI unchanged; 4 of 25 measured diet
• S32European Journal of Medical Research 2026: systematic review of sensor use in people without diabetes (UNVERIFIED live fetch, snippet only)opened, quote confirmedSensor use may lower mean glucose; no change in BMI or variability; glycaemic benefit in prediabetes, none in normoglycaemic adults
• S13ZOE METHOD 2024, Nature Medicine: 347 general adults, 18 weeksopened, quote confirmedA bundled personalized programme improved triglycerides, weight and HbA1c, not LDL; the sensor's share unidentified, contact unmatched
• S33Jospe 2024, Frontiers in Nutrition: 17 postmenopausal women with obesity, 16 weeks, exploratoryopened, quote confirmedThe one non-diabetic eating-pattern result opened is a small exploratory secondary analysis
• S31NIDDK: Diabetes Prevention Program summaryopened, quote confirmedLifestyle programme without any sensor lowered incident diabetes 58 percent over about 3 years in high-risk adults; the comparator any sensor claim must beat
• S15Hall 2021, Nature Medicine: 20 inpatient adults without diabetes, randomized crossover (PDF mirror)opened, quote confirmedHigher-carbohydrate diet gave higher glucose and insulin excursions yet about 689 kcal/day lower spontaneous intake than the ketogenic diet

The page may keep continuous glucose monitoring as an instrument for seeing meal responses; it may not imply that eating to the trace has been shown to change any outcome in a healthy adult, and a self-experiment with a sensor can establish a reproducible personal meal response only with randomized meal order, replicate blocks and the prior day's exercise and sleep held, and can never establish that flattening the trace lengthens life.

Monitor-guided eating has no outcome evidence in normoglycaemic adults: the randomized literature is a diabetes literature, the pooled effects are small and glycaemic, the normoglycaemic subgroup shows no glycaemic benefit, and where a sensor helps it is as an adherence channel inside a programme whose contact time was never matched. With 2.6 it writes the only admissible sensor self-experiment: randomized meal order, replicate blocks, the prior day held, and a conclusion about a personal meal response and never about lifespan.